<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004344.pub6" GROUP_ID="CF" ID="326202090514410816" MERGED_FROM="" MODIFIED="2016-08-01 16:10:47 +0100" MODIFIED_BY="Tracey Remmington" REVIEW_NO="0048" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.0">
<COVER_SHEET MODIFIED="2016-08-01 16:05:42 +0100" MODIFIED_BY="Tracey Remmington">
<TITLE>Treatment for avascular necrosis of bone in people with sickle cell disease</TITLE>
<CONTACT>
<PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Arturo</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Martí-Carvajal</LAST_NAME>
<SUFFIX>MD, MSc</SUFFIX>
<POSITION/>
<EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="VE">Venezuela</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-08-01 16:05:42 +0100" MODIFIED_BY="Tracey Remmington">
<PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Arturo</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Martí-Carvajal</LAST_NAME>
<SUFFIX>MD, MSc</SUFFIX>
<POSITION/>
<EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="VE">Venezuela</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12177" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Ivan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Solà</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher</POSITION>
<EMAIL_1>isola@santpau.cat</EMAIL_1>
<EMAIL_2>ensayos@cochrane.es</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Iberoamerican Cochrane Centre - Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT>
<ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP) - Universitat Autònoma de Barcelona</ORGANISATION>
<ADDRESS_1>Sant Antoni Maria Claret 167</ADDRESS_1>
<ADDRESS_2>Pavilion 18</ADDRESS_2>
<CITY>Barcelona</CITY>
<ZIP>08025</ZIP>
<REGION>Catalunya</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 935 537 814</PHONE_1>
<PHONE_2/>
<FAX_1>+34 935 537 809</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="3329B2B182E26AA200CD32E57C3A2C53" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Luis</FIRST_NAME>
<MIDDLE_INITIALS>H</MIDDLE_INITIALS>
<LAST_NAME>Agreda-Pérez</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>maria.agreda@cindu.com.ve</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Medicina Interna</DEPARTMENT>
<ORGANISATION>Hospital "Dr. Adolfo Prince Lara"</ORGANISATION>
<ADDRESS_1>Av. Salom</ADDRESS_1>
<ADDRESS_2/>
<CITY>Pto. Cabello</CITY>
<ZIP/>
<REGION>Edo. Carabobo</REGION>
<COUNTRY CODE="VE">Venezuela</COUNTRY>
<PHONE_1>+58 242 62 1033</PHONE_1>
<PHONE_2>+58 412 531 0376</PHONE_2>
<FAX_1>+58 242 62 1857</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-07-21 15:40:42 +0100" MODIFIED_BY="Tracey Remmington">
<UP_TO_DATE>
<DATE DAY="21" MONTH="7" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="27" MONTH="5" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="23" MONTH="7" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-07-21 15:40:52 +0100" MODIFIED_BY="Tracey Remmington">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-07-21 15:40:47 +0100" MODIFIED_BY="Tracey Remmington">
<DATE DAY="21" MONTH="7" YEAR="2016"/>
<DESCRIPTION>
<P>Only minor changes have been made throughout the review for this update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-07-21 15:40:52 +0100" MODIFIED_BY="Tracey Remmington">
<DATE DAY="21" MONTH="7" YEAR="2016"/>
<DESCRIPTION>
<P>A new search of the Cochrane Cystic Fibrosis and Genetic Disorders Haemoglobinopathies Trials Register identified no potentially eligible trials for inclusion in the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-06-30 10:23:30 +0100" MODIFIED_BY="Tracey Remmington">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-06-30 10:23:30 +0100" MODIFIED_BY="Tracey Remmington">
<DATE DAY="3" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>A search of the Cochrane Cystic Fibrosis and Genetic Disorders Haemoglobinopathies Trials Register did not identify any potentially eligible trials for inclusion in the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-06-30 10:23:28 +0100" MODIFIED_BY="Tracey Remmington">
<DATE DAY="3" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>For this update, the plain language summary has been updated and further minor changes have been made throughout the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-06-13 09:16:27 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-01-24 10:41:28 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="22" MONTH="5" YEAR="2012"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-05-22 09:05:34 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="7" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>A new search was carried out and minor revisions were made throughout the <LINK TAG="METHODS" TYPE="SECTION">Methods</LINK> section.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-05-22 09:05:34 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="7" MONTH="3" YEAR="2012"/>
<DESCRIPTION>
<P>A search of the Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register did not identify any potentially relevant trials for inclusion in the review. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-02-24 13:55:50 +0000" MODIFIED_BY="Tracey Remmington">
<DATE DAY="20" MONTH="9" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-09-20 10:21:55 +0100" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="26" MONTH="1" YEAR="2010"/>
<DESCRIPTION>
<P>A search of the Group's Haemoglobinopathies Trials Register did not identify any new references for this review. </P>
<P>One observational study (<LINK REF="STD-Mukisi_x002d_Mukasa-2009" TYPE="STUDY">Mukisi-Mukasa 2009</LINK>) was identified in Medline.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2009-12-02 14:16:47 +0000" MODIFIED_BY="Nikki Jahnke">
<DATE DAY="21" MONTH="4" YEAR="2009"/>
<DESCRIPTION>
<P>The search identified one new reference which has been included in the review (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>).<BR/>
<BR/>The 'Synopsis' (now 'Plain language summary'), 'Abstract', 'Background', 'Methods of review', 'Description of studies', 'Methodological quality of included studies'; 'Results', 'Discussion' and 'Reviewers' conclusions', sections have been updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-20 09:45:14 +0100" MODIFIED_BY="Tracey Remmington">
<DATE DAY="31" MONTH="7" YEAR="2006"/>
<DESCRIPTION>
<P>The search identified three new references. These were additional references to the ongoing study (Neumayr 2003).</P>
<P>The 'Methods of review' section has been updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-06-20 09:42:54 +0100" MODIFIED_BY="Tracey Remmington">
<DATE DAY="30" MONTH="6" YEAR="2005"/>
<DESCRIPTION>
<P>A search of the Group's Haemoglobinopathies Trials Register identified no additional trials eligible for inclusion in this review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2016-06-30 11:10:04 +0100" MODIFIED_BY="Tracey Remmington">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2016-06-30 11:10:04 +0100" MODIFIED_BY="Tracey Remmington">
<SOURCE MODIFIED="2009-02-14 17:49:04 +0000" MODIFIED_BY="[Empty name]">
<NAME>Centro Cochrane Iberoamericano</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>Academic.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2016-06-30 11:10:04 +0100" MODIFIED_BY="Tracey Remmington">
<NAME>National Institute for Health Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-08-01 16:07:20 +0100" MODIFIED_BY="Tracey Remmington">
<SUMMARY MODIFIED="2016-08-01 16:06:30 +0100" MODIFIED_BY="Tracey Remmington">
<TITLE>Treatments for people with sickle cell disease in whom poor blood supply to an area of bone leads to bone death</TITLE>
<SUMMARY_BODY MODIFIED="2016-08-01 16:06:30 +0100" MODIFIED_BY="Tracey Remmington">
<P>
<B>Review question</B>
<BR/>We reviewed the effects of treatments for avascular necrosis of bone in people with sickle cell disease.</P>
<P>
<B>Background</B>
<BR/>Many people with sickle cell disease experience bone death due to temporary or permanent loss of blood supply to parts of their bones. This can be very painful. The bones usually affected are the thigh bones at the hip joint and the arm bones at the shoulder joint. The aim of treatment is to stop the pain and maintain a mobile joint. Treatments include resting the joint, physiotherapy, the use of pain relief, joint replacements and bone grafts. However, complications from surgery may be more frequent in people with sickle cell disease. This is an update of a previously published Cochrane Review.</P>
<P>
<B>Search date</B>
<BR/>The evidence is current to: 27 May 2016.</P>
<P>
<B>Study characteristics</B>
<BR/>We found one eligible trial, published in 2006, which analysed data from 38 people from 32 different treatment centres from the United States of America. The trial compared a treatment of surgery and physical therapy with physical therapy on its own. This trial did not show that the addition of surgery to a physical therapy regimen could improve the outcome for people with sickle cell disease and avascular necrosis.</P>
<P>
<B>Key results</B>
<BR/>
</P>
<P>After a mean follow up of three years, the combination of surgery and physical therapies did not show clinical improvement when compared with physical therapy alone. Given that the results are imprecise, we are uncertain as to whether surgery and physical therapies in combination has an important effect on hip pain, vaso-occlusive crises and acute chest syndrome. Trial authors did not report information on mortality and quality of life.</P>
<P>
<B>Quality of the evidence</B>
<BR/>The limited number of participants included in the study led to imprecise results, therefore the confidence in the results is very low.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-08-01 16:06:25 +0100" MODIFIED_BY="Tracey Remmington">
<ABS_BACKGROUND MODIFIED="2016-08-01 16:06:25 +0100" MODIFIED_BY="Tracey Remmington">
<P>Avascular necrosis of bone is a frequent and severe complication of sickle cell disease and its treatment is not standardised. This is an update of a previously published Cochrane Review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-03-02 14:18:05 +0000" MODIFIED_BY="Nikki Jahnke">
<P>To determine the impact of any surgical procedure compared with other surgical interventions or non-surgical procedures, on avascular necrosis of bone in people with sickle cell disease in terms of efficacy and safety.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-06-30 10:26:59 +0100" MODIFIED_BY="Tracey Remmington">
<P>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register, comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Additional trials were sought from the reference lists of papers identified by the search strategy.</P>
<P>Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 27 May 2016.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2016-06-30 11:19:24 +0100" MODIFIED_BY="Tracey Remmington">
<P>Randomized clinical trials comparing specific therapies for avascular necrosis of bone in people with sickle cell disease.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-03-27 09:28:40 +0000" MODIFIED_BY="Tracey Remmington">
<P>Each author independently extracted data and assessed trial quality. Since only one trial was identified, meta-analysis was not possible.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-06-30 11:19:27 +0100" MODIFIED_BY="Tracey Remmington">
<P>One trial (46 participants) was eligible for inclusion. After randomization eight participants were withdrawn, mainly because they declined to participate in the trial. Data were analysed for 38 participants at the end of the trial. After a mean follow up of three years, hip core decompression and physical therapy did not show clinical improvement when compared with physical therapy alone using the score from the original trial (an improvement of 18.1 points for those treated with intervention therapy versus an improvement of 15.7 points with control therapy). There was no significant statistical difference between groups regarding major complications (hip pain, risk ratio 0.95 (95% confidence interval 0.56 to 1.60; vaso-occlusive crises, risk ratio 1.14 (95% confidence interval 0.72 to 1.80; very low quality of evidence); and acute chest syndrome, risk ratio 1.06 (95% confidence interval 0.44 to 2.56; very low quality of evidence)). This trial did not report results on mortality or quality of life.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-06-30 11:19:33 +0100" MODIFIED_BY="Tracey Remmington">
<P>We found no evidence that adding hip core decompression to physical therapy achieves clinical improvement in people with sickle cell disease with avascular necrosis of bone compared to physical therapy alone. However, we highlight that our conclusion is based on one trial with high attrition rates. Further randomized controlled trials are necessary to evaluate the role of hip-core depression for this clinical condition. Endpoints should focus on participants' subjective experience (e.g. quality of life and pain) as well as more objective 'time-to-event' measures (e.g. mortality, survival, hip longevity). The availability of participants to allow adequate trial power will be a key consideration for endpoint choice.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-08-01 16:06:55 +0100" MODIFIED_BY="Tracey Remmington">
<BACKGROUND MODIFIED="2016-08-01 16:06:37 +0100" MODIFIED_BY="Tracey Remmington">
<CONDITION MODIFIED="2016-06-30 11:01:05 +0100" MODIFIED_BY="Tracey Remmington">
<P>Sickle cell disease (SCD) is a group of genetic haemoglobin disorders (<LINK REF="REF-Pauling-1949" TYPE="REFERENCE">Pauling 1949</LINK>; <LINK REF="REF-Bunn-1997" TYPE="REFERENCE">Bunn 1997</LINK>; <LINK REF="REF-Serjeant-2001" TYPE="REFERENCE">Serjeant 2001</LINK>) which have their origins in sub-Saharan Africa and the Indian sub-continent (<LINK REF="REF-Stuart-2004" TYPE="REFERENCE">Stuart 2004</LINK>; <LINK REF="REF-Weatherall-2006" TYPE="REFERENCE">Weatherall 2006</LINK>). Population mobility has spread the disorders through Europe, Asia and the Americas.The term SCD includes sickle cell anaemia (Hb SS), haemoglobin S combined with haemoglobin C (Hb SC), haemoglobin S associated with ß thalassemia (Sß0 Thal and Sß+ Thal) and other double heterozygous conditions which cause clinical disease (<LINK REF="REF-Saunthararajah-2004" TYPE="REFERENCE">Saunthararajah 2004</LINK>; <LINK REF="REF-Serjeant-2001" TYPE="REFERENCE">Serjeant 2001</LINK>; <LINK REF="REF-Weatherall-2006" TYPE="REFERENCE">Weatherall 2006</LINK>). Haemoglobin S combined with normal haemoglobin (A) is known as sickle trait (AS), is asymptomatic and therefore not part of this review. The pathophysiology of SCD has been reviewed extensively (<LINK REF="REF-Hebbel-2004" TYPE="REFERENCE">Hebbel 2004</LINK>; <LINK REF="REF-Steinberg-2006" TYPE="REFERENCE">Steinberg 2006</LINK>; <LINK REF="REF-Stuart-2004" TYPE="REFERENCE">Stuart 2004</LINK>; <LINK REF="REF-Weatherall-2006" TYPE="REFERENCE">Weatherall 2006</LINK>). Although SCD is primarily a defect of red blood cells (a haematological defect), the changes in the red blood cells result in damage to blood vessels (vasculopathy) (<LINK REF="REF-Hebbel-2004" TYPE="REFERENCE">Hebbel 2004</LINK>) and severe osteo-articular injuries are often observed in the evolution of the SCD (<LINK REF="REF-Kim-2002" TYPE="REFERENCE">Kim 2002</LINK>; <LINK REF="REF-Meddeb-2003" TYPE="REFERENCE">Meddeb 2003</LINK>; <LINK REF="REF-Aguilar-2005b" TYPE="REFERENCE">Aguilar 2005b</LINK>). One of these injuries is avascular necrosis (AVN) or osteonecrosis; defined as massive necrosis of bone and bone marrow occurring as the only, or largely predominant, abnormality (<LINK REF="REF-Lafforgue-2006" TYPE="REFERENCE">Lafforgue 2006</LINK>), and its pathophysiology, with or without SCD, has been reviewed by many researchers (<LINK REF="REF-Lafforgue-2006" TYPE="REFERENCE">Lafforgue 2006</LINK>; <LINK REF="REF-Hernigou-2006" TYPE="REFERENCE">Hernigou 2006</LINK>).</P>
<P>In as many as 50% of the people with SCD, avascular necrosis (AVN) or osteonecrosis (disease resulting from the temporary or permanent loss of the blood supply to the bones) can cause chronic pain, particularly in the head of the femur (<LINK REF="REF-Vichinsky-1999" TYPE="REFERENCE">Vichinsky 1999</LINK>; Mukisi-Mukaza 2011; <LINK REF="REF-Mahadeo-2011" TYPE="REFERENCE">Mahadeo 2011</LINK>; Mouba 2011). The head of the humerus can also be affected by AVN (<LINK REF="REF-Pande-1998" TYPE="REFERENCE">Pande 1998</LINK>; Poignard 2012). It has been reported that the prevalence of humeral head necrosis occurs with equal frequency to hip necrosis and this reported frequency has varied from 2% to 17% in several studies of people with SS disease (<LINK REF="REF-Serjeant-1992" TYPE="REFERENCE">Serjeant 1992</LINK>). Humeral and femoral head avascular necroses tend to be associated with each other, the combination occurring in 8 out of 10 people with SCD (<LINK REF="REF-Serjeant-1992" TYPE="REFERENCE">Serjeant 1992</LINK>). Occasionally, the temporomandibular joint can also be involved (<LINK REF="REF-Baykul-2004" TYPE="REFERENCE">Baykul 2004</LINK>; <LINK REF="REF-el_x002d_Sabbagh-1989" TYPE="REFERENCE">el-Sabbagh 1989</LINK>). Vertebral bone compression and collapse induced by AVN in people with SCD has also been reported (<LINK REF="REF-Babhulkar-1998" TYPE="REFERENCE">Babhulkar 1998</LINK>; <LINK REF="REF-Emodi-2001" TYPE="REFERENCE">Emodi 2001</LINK>; <LINK REF="REF-Sadat_x002d_Ali-1994" TYPE="REFERENCE">Sadat-Ali 1994</LINK>).</P>
<P>The diagnosis of AVN must be precise, as the condition is complex requiring specific treatment according to the grade of joint involvement (<LINK REF="REF-Hattrup-1998" TYPE="REFERENCE">Hattrup 1998</LINK>; <LINK REF="REF-Plancher-1997" TYPE="REFERENCE">Plancher 1997</LINK>). There are a number of classifications or staging systems used for grading joint involvement. Some authors suggest that the ideal outcome is a pain-free preserved joint with good mobility (<LINK REF="REF-Plancher-1997" TYPE="REFERENCE">Plancher 1997</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-04-21 15:12:01 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The non-surgical approach includes observation, analgesics and limiting weight bearing over the joint. The surgical options include joint reconstruction (femoral head replacement, cup arthroplasty, replacement of the articular surface, and total hip replacement) as well as nucleus decompression, bone graft, vascularised bone grafts, electrical stimulation and osteotomy. There is more experience in treating AVN in the femoral head than in the humerus. In the latter, Hattrup reported the indications for replacement to be similar to those for any arthroplasty, i.e. pain and dysfunction that do not respond to non-surgical measures (<LINK REF="REF-Hattrup-1998" TYPE="REFERENCE">Hattrup 1998</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2016-08-01 16:06:37 +0100" MODIFIED_BY="Tracey Remmington">
<P>Joint replacement is not risk-free and complications (intra-operative bleeding, infection, loosening of the prosthesis and early loss of the joint replacement (<LINK REF="REF-Hernigou-1993" TYPE="REFERENCE">Hernigou 1993</LINK>)) may be more frequent in people with SCD. The treatment of AVN for people with SCD is not standardised. People with SCD suffering orthopedic complications require a multidisciplinary management (<LINK REF="REF-Sathappan-2006" TYPE="REFERENCE">Sathappan 2006</LINK>). This review, therefore, aims to address the question: what is the efficacy and safety of the surgical approaches compared to the available non-surgical treatments for people with SCD suffering from AVN?</P>
<P>This is an update of a previously published Cochrane Review (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2004" TYPE="REFERENCE">Martí-Carvajal 2004</LINK>; <LINK REF="REF-Mart_x00ed__x002d_Carvajal-2009" TYPE="REFERENCE">Martí-Carvajal 2009</LINK>; <LINK REF="REF-Mart_x00ed__x002d_Carvajal-2014" TYPE="REFERENCE">Martí-Carvajal 2014</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-04-21 15:14:39 +0100" MODIFIED_BY="Nikki Jahnke">
<P>To determine if any of the following treatments have any impact on avascular necrosis of bone in people with SCD in both the short- and the long-term (efficacy, safety, and adverse events): to compare any surgical with any non-surgical intervention, including combinations of surgical and non-surgical treatment. For this review, when available from the study reports, we accepted the definitions of short- and long-terms provided by the studies' authors.</P>
<P>Also, we sought to address the following with regard to the affected joint or bone and the stage of AVN:</P>
<OL>
<LI>the role of decompression;</LI>
<LI>the relative effectiveness of surgical approaches (only applicable for studies comparing two surgical approaches);and</LI>
<LI>types of prosthesis (glued or not, with or without bone grafts, etc.).</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2016-08-01 16:06:55 +0100" MODIFIED_BY="Tracey Remmington">
<SELECTION_CRITERIA MODIFIED="2016-06-30 11:04:44 +0100" MODIFIED_BY="Tracey Remmington">
<CRIT_STUDIES>
<P>Randomized controlled trials (RCTs) and quasi-randomized controlled trials (published or unpublished). Trials using quasi-randomization methods such as alternation were included if there was sufficient evidence that the treatment and comparison groups were comparable in terms of clinical status.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-12-19 10:39:10 +0000" MODIFIED_BY="[Empty name]">
<P>People of all ages and both sexes, in any setting, with SCD-related AVN. Diagnoses of SCD should be proven by electrophoresis and sickle solubility test, with family studies or deoxyribonucleic acid (DNA) tests as appropriate.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-04-21 15:15:25 +0100" MODIFIED_BY="Nikki Jahnke">
<P>Trials in which one surgical approach has been compared to another, or to a non-surgical approach, or where two non-surgical approaches have been compared.</P>
<P>Surgical treatment currently included: joint reconstruction (femoral head replacement, cup arthroplasty, articular surface replacement and total hip replacement); and its alternatives (nucleus decompression, bone graft, vascularized bone grafts and osteotomy).</P>
<P>Non-surgical treatment currently included: observation; analgesic drugs; electrical stimulation; physiotherapy; resting of the joint; red blood cell transfusion and stem cell transplant; treatment to prevent sickling; and bisphosphonates such as pamidronate.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-06-30 11:04:44 +0100" MODIFIED_BY="Tracey Remmington">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2016-06-30 11:04:44 +0100" MODIFIED_BY="Tracey Remmington">
<OL>
<LI>Pain</LI>
<OL>
<LI>presence and level of pain</LI>
<LI>use of analgesia during the first two weeks (doses of opioids will be converted into morphine equivalents to facilitate comparisons)</LI>
<OL>
<LI>weak opioids, e.g. codeine and tramadol</LI>
<LI>strong opioids, e.g. morphine and pethidine</LI>
<LI>acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) (open or selective Cox 2-inhibitors)</LI>
<LI>other analgesics</LI>
</OL>
</OL>
<LI>Death and cause of death</LI>
<LI>Adverse events, the events will be classified as: immediate (less than 24 hours post-intervention); early (one to eight days after intervention); and long-term (more than eight days after intervention). Our definition of immediate, early, and long term is arbitrary.</LI>
<OL>
<LI>prevalence and timing of joint loosening</LI>
<LI>bone fracture</LI>
<LI>infections</LI>
<LI>intra-operative bleeding</LI>
<LI>complications of SCD during hospital admission, e.g. painful crises, acute chest syndrome and stroke</LI>
<LI>related to analgesia</LI>
</OL>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-04-21 15:16:15 +0100" MODIFIED_BY="Nikki Jahnke">
<OL>
<LI>Quality of life</LI>
<OL>
<LI>general function (such as ability to continue in employment)</LI>
<LI>mobility</LI>
<LI>psychological measures</LI>
</OL>
<LI>Time in hospital</LI>
<OL>
<LI>total time spent in hospital</LI>
<LI>number of visits to hospital during the first eight weeks post-op</LI>
</OL>
<LI>Joint function: range of movement</LI>
</OL>
<P>It was planned that outcome data would be grouped into those measured at up to one month, then at one, three, six, twelve months and annually thereafter. If outcome data were recorded at other time periods, then consideration would have been given to examining these as well.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-08-01 16:06:55 +0100" MODIFIED_BY="Tracey Remmington">
<ELECTRONIC_SEARCHES MODIFIED="2016-08-01 16:06:55 +0100" MODIFIED_BY="Tracey Remmington">
<P>Relevant trials were identified from the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register using the terms: (sickle cell OR (haemoglobinopathies AND general)) AND avascular necrosis.</P>
<P>The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library) and weekly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences: the European Haematology Association conference; the American Society of Hematology conference; the British Society for Haematology Annual Scientific Meeting; the Caribbean Health Research Council Meetings; and the National Sickle Cell Disease Program Annual Meeting. For full details of all searching activities for the register, please see the relevant section of the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/CF/frame.html">Cochrane Cystic Fibrosis and Genetic Disorders Group Module</A>.</P>
<P>Date of the most recent search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register: 27 May 2016.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-06-20 09:49:44 +0100" MODIFIED_BY="Tracey Remmington">
<P>The bibliographic references of all retrieved literature were reviewed for additional reports of trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-06-30 11:19:48 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY_SELECTION MODIFIED="2008-06-20 09:52:35 +0100" MODIFIED_BY="Tracey Remmington">
<P>The authors screened the search results for potentially relevant trials and independently assessed them for inclusion or exclusion, using a pre-designed eligibility form based on the inclusion criteria. We resolved disagreements through discussion to reach a consensus.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-02-27 04:42:22 +0000" MODIFIED_BY="Tracey Remmington">
<P>Arturo Martí-Carvajal (AMC) and Ivan Solà (IS) designed a standard data extraction form and Luis Agreda Pérez (LAP) validated it. Each author used this form to extract data from each relevant study. We independently extracted information from the papers and AMC contacted the lead author of the included trial for further information (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>). We extracted information on study design and participant characteristics (age, sex, type of SCD (SS, SC, Sbß+ and Sbß0), the joint involved, and AVN score).</P>
<P>AMC entered the data into Review Manager, which was checked by IS and LAP (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). The <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table was completed using the 'Sheet to enter data for performing a Cochrane review' software (<LINK REF="REF-Zavala-2006" TYPE="REFERENCE">Zavala 2006</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-06-30 11:19:48 +0100" MODIFIED_BY="Tracey Remmington">
<P>Two review authors (AMC, IS) assessed every study using a simple form and followed the domain-based evaluation as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions 5.0.1</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We assessed the following domains as having either a low, unclear or high risk of bias:</P>
<OL>
<LI>randomization;</LI>
<LI>concealment of allocation;</LI>
<LI>blinding (of participants, assessors and providers of care);</LI>
<LI>incomplete outcome data.</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="4">1. Randomization</HEADING>
<P>'Low risk' (if a person who was not otherwise involved in the recruitment of participants performed one of the following procedures): if the allocation sequence was, for example, generated by a computer or random number table, by drawing of lots, by tossing of a coin, by the shuffling of cards, or the throwing of a dice.<BR/>'Unclear risk': if the trial was described as randomized, but the method used for the allocation sequence generation was not described.<BR/>'High risk': if a system involving dates, names, or admittance numbers were used for the allocation of participants.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Concealment of allocation</HEADING>
<P>'Low risk': participants and researchers were unaware of participants' future allocation to condition until after decisions about eligibility were made and informed consent was obtained.<BR/>'Unclear risk': allocation concealment measures were not described in detail.<BR/>'High risk': allocation was not concealed from either participants before informed consent or from researchers before decisions about inclusion were made.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Blinding (of participants, assessors and providers of care)</HEADING>
<P>'Low risk': assessor blind to condition.<BR/>'Unclear risk': blinding of assessor not reported and information not available from researchers.<BR/>'High risk': assessor not blind to condition.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Incomplete outcome data</HEADING>
<P>'Low risk': losses to follow up were equally distributed between treatment and comparison groups;<BR/>'Unclear risk': information about losses to follow up unavailable; and<BR/>'High risk': significant or unevenly distributed losses to follow up.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-02-27 04:43:17 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Review Manager 5.1 was used to enter and analyse the included data (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). For binary outcomes, we estimated the treatment effects using risk ratios (RR). For continuous outcomes, we estimated the treatment effects by calculating the mean differences. We could not examine data for skewness using the means and standard deviations because it is not appropriate for change from baseline measures (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>As only one trial was identified, it was not possible to perform any pooled analysis. Below, we describe our methodological plan for when more trials are included in the review in the future.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2014-06-13 09:18:08 +0100" MODIFIED_BY="[Empty name]">
<P>One author (AMC) contacted the lead author of the included trial for further information (<LINK REF="REF-Neumayr-2009-_x005b_pers-comm_x005d_" TYPE="REFERENCE">Neumayr 2009 [pers comm]</LINK>). If in future we require further data on any of the included trials we will contact the relevant authors. We will seek data on the number of participants by allocated treatment group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow up. If we are not able to do so, we will record for each trial, whether the results pertain to an intention-to-treat analysis or to a available-cases analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-04-21 15:20:47 +0100" MODIFIED_BY="Nikki Jahnke">
<P>If in future, sufficient trials are included in the review, we will quantify the impact of statistical heterogeneity using the I<SUP>2</SUP> statistic, which describes the percentage of total variation across studies that are due to heterogeneity rather than sampling error (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-04-21 15:21:16 +0100" MODIFIED_BY="Nikki Jahnke">
<P>When sufficient trials are included in the review, we plan to use a funnel plot to explore the possibly of publication bias.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-06-20 09:58:50 +0100" MODIFIED_BY="Tracey Remmington">
<P>If the identified studies are sufficiently comparable, we will summarize their findings using a fixed effects model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-04-21 15:21:54 +0100" MODIFIED_BY="Nikki Jahnke">
<P>In case of significant heterogeneity, we will devote further research to identify possible causes of heterogeneity such as the impact of participants' characteristics. We will perform subgroup analyses by type of SCD (SS, SC, Sbß+ and Sbß0), age, setting, the joint involved, AVN score and type of surgery.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-06-20 09:59:17 +0100" MODIFIED_BY="Tracey Remmington">
<P>We also plan to perform a sensitivity analysis based on the methodological quality of the trials, including and excluding quasi-randomized trials. We will perform further sensitivity analysis according to whether the trial results were calculated using intention-to-treat analysis (ITT) or not.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-06-30 11:26:13 +0100" MODIFIED_BY="Tracey Remmington">
<STUDY_DESCRIPTION MODIFIED="2016-06-30 11:05:40 +0100" MODIFIED_BY="Tracey Remmington">
<SEARCH_RESULTS MODIFIED="2009-12-28 16:56:54 +0000" MODIFIED_BY="[Empty name]">
<P>We identified seven potentially eligible studies in the bibliographical searches, of which one (National Osteonecrosis Trial in Sickle Cell Anemia Study Group) was eligible for inclusion in the review (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-06-30 11:05:40 +0100" MODIFIED_BY="Tracey Remmington">
<P>One trial (National Osteonecrosis Trial in Sickle Cell Anemia Study Group), including 46 participants was eligible for inclusion in the review (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>). The included trial was first incorporated into the review in the 2008 update (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Trial Design</HEADING>
<P>The trial was conducted in 32 SCD centers across the United States of America, from June 1998 to June 2002 in people with SCD (hemoglobin-SS, hemoglobin-SC, or hemoglobin-S/ß0-thalassemia). The authors of the included trial indicated that it was underpowered by stating "It is possible that our inability to demonstrate a difference in outcome between the two groups was due to a type-2 statistical error. The sample size required to detect this 2.4-point difference in mean change scores with a power of 80% and a type-1 error of 0.05 would be more than 1000 in each group" (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>Four hundred and twenty individuals were screened for osteonecrosis of the femoral head of the hip; 176 met the inclusion criteria; 46 (26%) of the eligible participants were enrolled in the study. The mean age of participant was 26 years. If participants had bilateral disease, the more symptomatic hip was included in the trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Participants in the intervention group received hip core decompression and physical therapy. They were also admitted to hospital for one day preoperatively for evaluation, hydration and transfusion. Participants with hemoglobin-SS or hemoglobin-S/b0-thalassemia underwent a single preoperative transfusion to bring the haemoglobin level to approximately 100 g/L. For participants with hemoglobin-SC or hemoglobin-S/b+-thalassemia whose baseline haemoglobin concentration was higher than 100 g/L, partial exchange transfusion was performed to avoid raising the haemoglobin concentration to an unsafe level. The control group received physical therapy alone with matching based on the Steinberg stage, assigned at the local center. However, because there is some variation in the interpretation of the Steinberg staging system (especially in distinguishing Stage II from III), trial investigators included an expert panel who examined these grades and in some cases re-graded the stages. We contacted the investigators for more information and were told that the panel were blind to the randomization and read the baseline films in a few batches at the end of the study. The investigators felt that consistency and reliability on the staging was important for analysis, especially since Stage IV was an exclusion criteria and below Stage IV was eligible for inclusion; the investigators confirmed that none of the study hips were Stage IV.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>The main outcome measure was clinical improvement measured by the Children's Hospital Oakland Hip Evaluation Scale (CHOHES) score (<LINK REF="REF-Aguilar-2005a" TYPE="REFERENCE">Aguilar 2005a</LINK>). This is a 100-point scale for assessing pain, function, strength, and range of motion (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). The secondary outcome was hip survival.</P>
<P>For further details see the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-03-07 14:15:58 +0000" MODIFIED_BY="[Empty name]">
<P>Six studies have been excluded from the review. For further details see the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-06-30 11:26:13 +0100" MODIFIED_BY="Tracey Remmington">
<P>The risk of bias of the included trial (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>) is summarised in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>. This trial had some methodological inadequacy and following the risk of bias methodology listed above, we classified it as trial with high risk of bias.</P>
<ALLOCATION MODIFIED="2016-06-30 11:26:13 +0100" MODIFIED_BY="Tracey Remmington">
<P>Trial investigators confirmed that participants were randomized by stage of AVN (I, II, III; those with stage IV were excluded) to either the surgical or conservative-therapy arm. A list of random numbers was generated for each stage of AVN (confirmed by contact with authors). This stratified assignment aimed to ensure equal numbers of participants with Stage I, Stage II and Stage III in each of the treatment arms (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Participating centers called the Co-ordinating Center for arm assignment. If the initial clinical examination revealed AVN of the contralateral hip, the most symptomatic hip was randomized. The participant was randomized to surgery or conservative therapy based on the stage of the symptomatic hip.  </P>
<P>After radiologic staging and informed consent was obtained, participating centers called the Co-ordinating Center for arm assignment.</P>
<P>Therefore, randomization and allocation concealment are assessed as having a low risk of bias.</P>
</ALLOCATION>
<BLINDING MODIFIED="2009-04-21 15:42:46 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The coordinating center&#8217;s radiology committee (three radiologists) were blinded to the reports from the participating centers. Blinding of other trial personnel and participants was not possible given treatments.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-04-21 15:43:37 +0100" MODIFIED_BY="Nikki Jahnke">
<P>The study enrolled 46 participants. After randomization, eight participants (26% in experimental group (6/23) and 9% in control group (2/23)) withdrew from the trial, mainly because they declined to participate in the trial. Thirty-eight participants (38 hips), 17 in experimental group (17/23) and 21(21/23) in control group, completed the treatment protocol. This trial used per protocol analysis (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). Given this imbalance between comparison groups regarding trial completion, the trial had a high risk of bias in this domain.</P>
</EXCLUSIONS>
<OTHER_BIAS_SOURCES MODIFIED="2009-12-28 17:03:08 +0000" MODIFIED_BY="[Empty name]">
<P>Participants were graded at the local center according to Steinberg stage. However, because there is some variation in the interpretation of the Steinberg staging system (especially in distinguishing Stage II from III), trial investigators included an expert panel who examined these grades and in some cases re-graded the stages. We contacted the investigators for more information and were told that the panel were blind to the randomization and read the baseline films in a few batches at the end of the study. The investigators felt that consistency and reliability on the staging was important for analysis, especially since Stage IV was an exclusion criteria and below Stage IV was eligible for inclusion; the investigators confirmed that none of the study hips were Stage IV (<LINK REF="REF-Neumayr-2009-_x005b_pers-comm_x005d_" TYPE="REFERENCE">Neumayr 2009 [pers comm]</LINK>). We are therefore happy that there is no potential risk of bias from the retrospective re-grading of any participants.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-06-30 11:20:34 +0100" MODIFIED_BY="Tracey Remmington">
<P>Results are based on one trial (38 participants).</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Pain</HEADING>
<P>The included trial did not show differences in the pain measures between the groups compared.</P>
<P>The main outcome in the NOTSCA study was the clinical improvement in general function measured by means of the CHOHES score, a multi-outcome clinical score that measured pain, but also joint motion, function and strength (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>). The authors defined a clinical success with a improvement of 15 points at follow up. After an average of 27 months of follow up, participants in the intervention group showed a mean improvement of 18 points (18.1 ±19.8) compared with an improvement of 15 points (15.7 ±19.6) showed by those in the control group. The observed difference between groups was not significant. It is worthy to comment that it is likely that these results are skewed, as they only reported data for the participants who received one surgical intervention (the analyses excluded the participants who required total hip replacement).</P>
<P>However, authors reported pain as a complication related to the treatment received, and did not observe a significant difference between groups, RR 0.95 (95% CI 0.58 to 1.60) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Death and cause of death</HEADING>
<P>The included trial did not assess this outcome (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>). There were three deaths (one in the intervention group and two in the control group); two from acute chest syndrome, and one from an unknown cause. However, these events occurred more than three years after study entry.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Adverse events</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a<I>.</I> prevalence and timing of joint loosening</HEADING>
<P>The trial investigators did not report any intra-operative or immediate post-operative complications in those participants receiving the hip core decompression (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>). During the post-operative period (30 days), two participants were re-admitted to the hospital due to bilateral hip pain, and a further post-operative infection was documented. Six of the randomized participants (15.8%) required an additional surgical intervention. Three participants assigned to the control group received hip core decompression (the assessed intervention) during the study. The surgical intervention failed in three participants of the intervention group and they underwent a total hip replacement due to the recurrent pain produced by an osteonecrosis of the femoral head.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b. bone fracture</HEADING>
<P>This outcome was not reported in the included trial (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">c. infections</HEADING>
<P>Post-operative infection was documented in one participant in intervention group. Drainage from of the hip core incision was performed on the 42nd post-operative day.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">d. intra-operative bleeding</HEADING>
<P>The average blood loss was reported to be 48 mL in the hip core decompression group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">e. complications of SCD during hospital admission, e.g. painful crises, acute chest syndrome and stroke</HEADING>
<P>There was no significant difference between groups regarding vaso-occlusive crisis, RR 1.14 (95% CI 0.72 to 1.80) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), or acute chest syndrome, RR 1.06 (95% CI 0.44 to 2.56) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Stroke was not reported (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">f. related to analgesia</HEADING>
<P>This outcome was not reported by the trialists (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Quality of life</HEADING>
<P>This outcome was not reported by the included trial (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>)<I>
<B>.</B>
</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Time in hospital</HEADING>
<P>The length of stay for the participants who received hip core decompression was 4.6 days (range: 2 to 10 days) (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Joint function: range of movement</HEADING>
<P>This outcome was measured by means of the CHOHES score in the NOTSCA study (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>), as a measure of clinical improvement. The observed differences at the end of the study were not significant (see above in 'Primary outcome 1. Pain' for further details).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-06-30 11:07:35 +0100" MODIFIED_BY="Tracey Remmington">
<P>This review has identified only one randomized controlled trial (RCT) which met the pre-defined inclusion criteria (<LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK>). However, this RCT did not show any significant differences between the comparison groups (hip core decompression and physical therapy versus physical therapy alone). Two reasons could explain these results. Firstly, this RCT was underpowered to detect a difference in treatments. Therefore, this RCT cannot be considered a 'negative trial' given that it was not sufficiently large enough to detect clinically relevant differences (<LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>). Secondly, the trial had some methodological limitation regarding a significant imbalance in participant withdrawals.</P>
<P>The number of people worldwide who suffer from this severe complication of sickle cell disease (SCD), which results in chronic pain and deterioration of quality of life varies in different reports from 2.9% to 41%; indeed, avascular necrosis (AVN) of the femoral head is quite common among Kuwaiti people with SCD (<LINK REF="REF-Marouf-2003" TYPE="REFERENCE">Marouf 2003</LINK>), and people from Africa, the Mediterranean and the USA (<LINK REF="REF-Athanassiou-2002" TYPE="REFERENCE">Athanassiou 2002</LINK>; <LINK REF="REF-Knox_x002d_Macaulay-1983" TYPE="REFERENCE">Knox-Macaulay 1983</LINK>; <LINK REF="REF-Koduri-2001" TYPE="REFERENCE">Koduri 2001</LINK>; <LINK REF="REF-Powars-2002" TYPE="REFERENCE">Powars 2002</LINK>). The natural history of AVN in people with SCD shows that symptomatic osteonecrosis of the hip has a high likelihood of leading to femoral head collapse, necessitating surgical intervention (<LINK REF="REF-Hernigou-2006" TYPE="REFERENCE">Hernigou 2006</LINK>; <LINK REF="REF-Ilyas-2002" TYPE="REFERENCE">Ilyas 2002</LINK>), but this point could be not confirmed in the light of the evidence identified in this review. There is an argument for early prevention and effective treatment for people with SCD with suspected AVN, but as yet no evidence base to support operative intervention. Surgical approaches have previously been reported to have many types of complications and therefore require proper evaluation (<LINK REF="REF-Al_x002d_Mousawi-2002" TYPE="REFERENCE">Al-Mousawi 2002</LINK>; <LINK REF="REF-Vichinsky-1999" TYPE="REFERENCE">Vichinsky 1999</LINK>).</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-06-30 11:20:38 +0100" MODIFIED_BY="Tracey Remmington">
<IMPLICATIONS_PRACTICE MODIFIED="2016-06-30 11:07:14 +0100" MODIFIED_BY="Tracey Remmington">
<P>Based on one trial, which was under-powered, the question of a possible beneficial or deleterious effect of hip core decompression remains open. Until further evidence is provided to prove that the intervention is effective, core decompression combined with physical therapy should not be used to treat people with SCD suffering AVN of the bone.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-06-30 11:20:38 +0100" MODIFIED_BY="Tracey Remmington">
<P>This systematic review has identified the need for well-designed, adequately-powered randomized clinical trial to assess the benefits and harms of the variety of treatments for avascular necrosis in people with SCD.</P>
<P>Trialists should consider including endpoints that focus on the subjective experience of participants (such as quality of life, and pain) as well as more objective 'time-to-event' measures (such as mortality, survival, or hip longevity). The availability of participants to allow adequate trial power will be a key consideration during endpoint choice. Further RCTs are necessary to evaluate the role of hip-core depression for this clinical condition.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-08-01 16:07:09 +0100" MODIFIED_BY="Tracey Remmington">
<P>The authors would like to take this opportunity to express their gratitude to:<BR/>1. Dr Lynne Neumayr, corresponding author of <LINK REF="STD-NOTSCA--2006" TYPE="STUDY">NOTSCA 2006</LINK> for her personal communication which improved the quality of this Cochrane Review.<BR/>2. Miss Tracey Remmington and Mrs Nikki Jahnke from the Cochrane Cystic Fibrosis and Genetic Disorders Group for their help in the update of this Cochrane Review.<BR/>3. Dr Ian Hambleton, Editor of this review.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-08-01 16:07:20 +0100" MODIFIED_BY="Tracey Remmington">
<P>All authors: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-03-26 15:01:13 +0000" MODIFIED_BY="[Empty name]">
<P>Dr Arturo Martí-Carvajal took the lead on writing up this update, with comments on the draft versions from both Mr Ivan Solà and Dr Luis Agreda-Pérez.</P>
<P>Dr Arturo Martí-Carvajal acts as guarantor of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2008-06-20 09:42:21 +0100" MODIFIED_BY="Tracey Remmington"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-08-01 16:10:47 +0100" MODIFIED_BY="Tracey Remmington">
<STUDIES MODIFIED="2012-03-07 14:11:32 +0000" MODIFIED_BY="Nikki Jahnke">
<INCLUDED_STUDIES MODIFIED="2012-02-27 04:11:09 +0000" MODIFIED_BY="Tracey Remmington">
<STUDY DATA_SOURCE="MIX" ID="STD-NOTSCA--2006" MODIFIED="2012-02-27 04:11:09 +0000" MODIFIED_BY="Tracey Remmington" NAME="NOTSCA  2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Aguilar C, Neumayr L, Vichinsky E</AU>
<TI>Evaluation of hip function in sickle cell patients with avascular necrosis of the hip [abstract]</TI>
<SO>Proceedings of the 23rd National Sickle Cell Disease Program Annual Meeting</SO>
<YR>1999</YR>
<PG>55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3161988"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-27 10:15:08 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Neumayr L, Robertson S, Aguilar C, Earles A, Jergesen H, Haberkern CM et al</AU>
<TI>Progression of avascular necrosis of the hip in sickle cell disease: 3 year follow-up of randomized trial of aggressive physical therapy and hip coring decompression [abstract]</TI>
<SO>29th Annual Meeting of the National Sickle Cell Disease Program; 2006 April 8-12; Memphis, USA.</SO>
<YR>2006</YR>
<PG>Abstract 148</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3161989"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-27 10:19:09 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Neumayr L, Robertson S, Aguilar C, Earles A, Vichinsky E, and the National Decompression Coring vs Conservative Therapy for AVN in Sickle Cell Disease Study Group</AU>
<TI>Preliminary perioperative safety data from the National Necrosis Trial in sickle cell anemia [abstract]</TI>
<SO>Proceedings of the 25th National Sickle Cell Disease Program Annual Meeting; 2001</SO>
<YR>2001</YR>
<VL>Abstract 161</VL>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3161990"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-27 10:15:21 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Neumayr LD, Aguilar C, Earles A, Jergesen H, Hoffinger S, Haberkern CM et al</AU>
<TI>Final enrollment from the national avascular necrosis trial in sickle cell anemia [abstract]</TI>
<SO>27th Annual Meeting of the National Sickle Cell Disease Program; 2004 April 18-21; Los Angeles, California</SO>
<YR>2004</YR>
<PG>168</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3161991"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2012-02-27 04:11:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Neumayr LD, Aguilar C, Earles AN, Jergesen HE, Haberkern CM, Kammen BF et al</AU>
<TI>Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment</TI>
<SO>Journal of Bone and Joint Surgery</SO>
<YR>2006</YR>
<VL>88</VL>
<NO>12</NO>
<PG>2573-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3161992"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-27 10:15:31 +0000" MODIFIED_BY="Tracey Remmington" NOTES="&lt;p&gt;. .&lt;/p&gt;" NOTES_MODIFIED="2009-03-27 10:15:31 +0000" NOTES_MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neumayr LD, Aguilar C, Jergesen H, Hoffinger S, Haberkern CM, Vichinsky EP</AU>
<TI>Final enrollment from the National Avascular Necrosis Trial in Sickle Cell Anemia [abstract]</TI>
<SO>Blood</SO>
<YR>2003</YR>
<VL>102</VL>
<NO>11</NO>
<PG>Abstract 2830</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3161993"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-27 10:15:41 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Vichinsky EP, Neumayr L, Earles A, Aguilar C, Hoffinger S, Jergesen H et al</AU>
<TI>Progression of avascular necrosis of the hip in sickle cell disease: 2 year follow-up of randomized trial of aggressive physical therapy and hip coring decompression [abstract]</TI>
<SO>28th Annual Meeting of the National Sickle Cell Disease Program; 2005 April 9-13; Cincinnati, Ohio</SO>
<YR>2005</YR>
<PG>148</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3161994"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3161987"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-03-07 14:11:32 +0000" MODIFIED_BY="Nikki Jahnke">
<STUDY DATA_SOURCE="PUB" ID="STD-Al-Momen-1997" NAME="Al Momen 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al Momen AK, Ajarim DS, Diab AR, Harakati H, AI Abdulkareem H, Fawzi E</AU>
<TI>Clodronate in the management of acute sickle cell-related bone pain [abstract]</TI>
<SO>Blood</SO>
<YR>1997</YR>
<VL>90</VL>
<NO>10 Suppl 1</NO>
<PG>22b</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3161996"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3161995"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x002d_Mousawi-2007" MODIFIED="2009-03-27 10:14:46 +0000" MODIFIED_BY="Tracey Remmington" NAME="Al-Mousawi 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-03-27 10:14:46 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Al-Mousawi FR, Malki AA</AU>
<TI>Managing femoral head osteonecrosis in patients with sickle cell disease</TI>
<SO>Surgeon</SO>
<YR>2007</YR>
<VL>5</VL>
<NO>5</NO>
<PG>282-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3161998"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3161997"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barnes-1965" NAME="Barnes 1965" YEAR="1965">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barnes PM, Hendrickse RG, Watson-Williams EJ</AU>
<TI>Low-molecular-weight dextran in treatment of bone-pain crises in sickle-cell disease. A double-blind trial</TI>
<SO>Lancet</SO>
<YR>1965</YR>
<VL>2</VL>
<NO>7425</NO>
<PG>1271-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3162000"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3161999"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eke-2000" NAME="Eke 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eke FU, Obamyonyi A, Eke NN, Oyewo EA</AU>
<TI>An open comparative study of dispersible piroxicam versus soluble acetylsalicylic acid for the treatment of osteoarticular painful attack during sickle cell crisis</TI>
<SO>Tropical Medicine &amp; International Health</SO>
<YR>2000</YR>
<VL>5</VL>
<NO>2</NO>
<PG>81-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3162002"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3162001"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mukisi_x002d_Mukasa-2009" MODIFIED="2012-02-27 04:11:47 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Mukisi-Mukasa 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-02-27 04:11:47 +0000" MODIFIED_BY="Nikki Jahnke" PRIMARY="NO" TYPE="OTHER">
<AU>Mukisi-Mukaza M, Manicom O, Alexis C, Bashoun K, Donkerwolcke M, Burny F</AU>
<TI>Treatment of Sickle cell disease's hip necrosis by core decompression: A prospective case-control study</TI>
<SO>Orthopaedics &amp; Traumatology, Surgery &amp; Research</SO>
<YR>2009</YR>
<VL>95</VL>
<NO>7</NO>
<PG>498-504</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3162004"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3162003"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Opio-1972" MODIFIED="2009-03-27 10:14:10 +0000" MODIFIED_BY="Tracey Remmington" NAME="Opio 1972" YEAR="1972">
<REFERENCE MODIFIED="2009-03-27 10:14:10 +0000" MODIFIED_BY="Tracey Remmington" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Opio E, Barnes PM</AU>
<TI>Intravenous urea in treatment of bone-pain crises of sickle-cell disease</TI>
<SO>Lancet</SO>
<YR>1972</YR>
<VL>2</VL>
<NO>7769</NO>
<PG>160-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3162006"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3162005"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-07-26 12:58:57 +0100" MODIFIED_BY="Tracey Remmington">
<ADDITIONAL_REFERENCES MODIFIED="2012-02-27 04:42:46 +0000" MODIFIED_BY="Nikki Jahnke">
<REFERENCE ID="REF-Aguilar-2005a" MODIFIED="2009-03-27 10:00:51 +0000" MODIFIED_BY="Tracey Remmington" NAME="Aguilar 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Aguilar CM, Neumayr LD, Eggleston BE, Earles AN, Robertson SM, Jergesen HE et al</AU>
<TI>Clinical evaluation of avascular necrosis in patients with sickle cell disease: Children's Hospital Oakland Hip Evaluation Scale -a modification of the Harris Hip Score</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>2005</YR>
<VL>86</VL>
<NO>7</NO>
<PG>369-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aguilar-2005b" MODIFIED="2009-03-27 10:01:57 +0000" MODIFIED_BY="Tracey Remmington" NAME="Aguilar 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Aguilar C, Vichinsky E, Neumayr L</AU>
<TI>Bone and joint disease in sickle cell disease</TI>
<SO>Hematology/Oncology Clinics of North America</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>5</NO>
<PG>929-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Al_x002d_Mousawi-2002" NAME="Al-Mousawi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Al-Mousawi F, Malki A, Al-Aradi A, Al-Bagali M, Al-Sadadi A, Booz MM</AU>
<TI>Total hip replacement in sickle cell disease</TI>
<SO>International Orthopaedics</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>3</NO>
<PG>157-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alderson-2004" MODIFIED="2009-03-27 10:02:11 +0000" MODIFIED_BY="Tracey Remmington" NAME="Alderson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Alderson P</AU>
<TI>Absence of evidence is not evidence of absence</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7438</NO>
<PG>476-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Athanassiou-2002" NAME="Athanassiou 2002" TYPE="JOURNAL_ARTICLE">
<AU>Athanassiou-Metaxa M, Kirkos J, Koussi A, Hatzipantelis E, Tsatra I, Economou M</AU>
<TI>Avascular necrosis of the femoral head among children and adolescents with sickle cell disease in Greece</TI>
<SO>Haematologica</SO>
<YR>2002</YR>
<VL>87</VL>
<NO>7</NO>
<PG>771-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Babhulkar-1998" NAME="Babhulkar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Babhulkar SS, Pande SK, Pande KC</AU>
<TI>Osteonecrosis of vertebral end plates in patients of sickle cell haemoglobinopathy</TI>
<SO>Journal of Bone and Joint Surgery (Br)</SO>
<YR>1998</YR>
<VL>80-B (1S)</VL>
<NO>Suppl I</NO>
<PG>73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baykul-2004" MODIFIED="2009-03-27 10:02:46 +0000" MODIFIED_BY="Tracey Remmington" NAME="Baykul 2004" TYPE="JOURNAL_ARTICLE">
<AU>Baykul T, Aydin MA, Nasir S</AU>
<TI>Avascular necrosis of the mandibular condyle causing fibrous ankylosis of the temporomandibular joint in sickle cell anemia</TI>
<SO>Journal of Craniofacial Surgery</SO>
<YR>2004</YR>
<VL>15</VL>
<NO>6</NO>
<PG>1052-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bunn-1997" NAME="Bunn 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bunn HF</AU>
<TI>Pathogenesis and treatment of sickle cell disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<NO>11</NO>
<PG>762-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-el_x002d_Sabbagh-1989" NAME="el-Sabbagh 1989" TYPE="JOURNAL_ARTICLE">
<AU>el-Sabbagh AM, Kamel M</AU>
<TI>Avascular necrosis of temporomandibular joint in sickle cell disease</TI>
<SO>Clinical Rheumatology</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>3</NO>
<PG>393-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Emodi-2001" NAME="Emodi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Emodi JI, Okoye IJ</AU>
<TI>Vertebral bone collapse in sickle cell disease: a report of two cases</TI>
<SO>East African Medicine Journal</SO>
<YR>2001</YR>
<VL>78</VL>
<NO>8</NO>
<PG>445-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hattrup-1998" NAME="Hattrup 1998" TYPE="JOURNAL_ARTICLE">
<AU>Hattrup SJ</AU>
<TI>Total shoulder arthroplasty</TI>
<SO>Orthopedic Clinics of North America</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>3</NO>
<PG>445-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hebbel-2004" MODIFIED="2009-03-27 10:03:44 +0000" MODIFIED_BY="Tracey Remmington" NAME="Hebbel 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hebbel RP, Osarogiagbon R, Kaul D</AU>
<TI>The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy</TI>
<SO>Microcirculation</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>2</NO>
<PG>129-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hernigou-1993" NAME="Hernigou 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hernigou P, Bachir D, Galacteros F</AU>
<TI>Avascular necrosis of the femoral head in sickle-cell disease. Treatment of collapse by the injection of acrylic cement</TI>
<SO>Journal of Bone and Joint Surgery (Br)</SO>
<YR>1993</YR>
<VL>75</VL>
<NO>6</NO>
<PG>875-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hernigou-2006" MODIFIED="2009-03-27 10:04:21 +0000" MODIFIED_BY="Tracey Remmington" NAME="Hernigou 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hernigou P, Habibi A, Bachir D, Galacteros F</AU>
<TI>The natural history of symptomatic osteonecrosis in adults with sickle-cell disease</TI>
<SO>Journal of Bone and Joint Surgery. American volume</SO>
<YR>2006</YR>
<VL>88</VL>
<NO>12</NO>
<PG>2565-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-02-27 04:41:30 +0000" MODIFIED_BY="Tracey Remmington" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ilyas-2002" NAME="Ilyas 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ilyas I, Moreau P</AU>
<TI>Simultaneous bilateral total hip arthroplasty in sickle cell disease</TI>
<SO>Journal of Arthroplasty</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>4</NO>
<PG>441-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kim-2002" MODIFIED="2009-03-27 10:07:58 +0000" MODIFIED_BY="Tracey Remmington" NAME="Kim 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kim SK, Miller JH</AU>
<TI>Natural history and distribution of bone and bone marrow infarction in sickle hemoglobinopathies</TI>
<SO>Journal of Nuclear Medicine</SO>
<YR>2002</YR>
<VL>43</VL>
<NO>7</NO>
<PG>896-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Knox_x002d_Macaulay-1983" NAME="Knox-Macaulay 1983" TYPE="JOURNAL_ARTICLE">
<AU>Knox-Macaulay HH</AU>
<TI>Sickle cell disease in Sierra Leone: a clinical and haematological analysis in older children and adults</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>1983</YR>
<VL>77</VL>
<NO>4</NO>
<PG>411-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koduri-2001" NAME="Koduri 2001" TYPE="JOURNAL_ARTICLE">
<AU>Koduri PR, Agbemadzo B, Nathan S</AU>
<TI>Hemoglobin S-C disease revisited: clinical study of 106 adults</TI>
<SO>American Journal of Hematology</SO>
<YR>2001</YR>
<VL>68</VL>
<NO>4</NO>
<PG>298-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lafforgue-2006" MODIFIED="2009-03-27 10:08:31 +0000" MODIFIED_BY="Tracey Remmington" NAME="Lafforgue 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lafforgue P</AU>
<TI>Pathophysiology and natural history of avascular necrosis of bone</TI>
<SO>Joint Bone Spine</SO>
<YR>2006</YR>
<VL>73</VL>
<NO>5</NO>
<PG>500-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mahadeo-2011" MODIFIED="2012-02-27 04:00:36 +0000" MODIFIED_BY="[Empty name]" NAME="Mahadeo 2011" TYPE="JOURNAL_ARTICLE">
<AU>Mahadeo KM, Oyeku S, Taragin B, Rajpathak SN, Moody K, Santizo R et al</AU>
<TI>Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease</TI>
<SO>American Journal of Hematology</SO>
<YR>2011</YR>
<VL>86</VL>
<NO>9</NO>
<PG>806-8</PG>
<IDENTIFIERS MODIFIED="2012-02-27 04:00:14 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER TYPE="PUBMED" VALUE="21850660"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marouf-2003" NAME="Marouf 2003" TYPE="JOURNAL_ARTICLE">
<AU>Marouf R, Gupta R, Haider MZ, Al-Wazzan H, Adekile AD</AU>
<TI>Avascular necrosis of the femoral head in adult Kuwaiti sickle cell disease patients</TI>
<SO>Acta Haematologica</SO>
<YR>2003</YR>
<VL>110</VL>
<NO>1</NO>
<PG>11-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meddeb-2003" MODIFIED="2009-03-27 10:09:04 +0000" MODIFIED_BY="Tracey Remmington" NAME="Meddeb 2003" TYPE="JOURNAL_ARTICLE">
<AU>Meddeb N, Gandoura N, Gandoura M, Sellami S</AU>
<TI>Osteoarticular manifestations of sickle cell disease</TI>
<SO>La Tunisie Médicale</SO>
<YR>2003</YR>
<VL>81</VL>
<NO>7</NO>
<PG>441-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neumayr-2009-_x005b_pers-comm_x005d_" MODIFIED="2009-12-14 14:14:11 +0000" MODIFIED_BY="Nikki Jahnke" NAME="Neumayr 2009 [pers comm]" TYPE="OTHER">
<AU>Neumayr LN (Department of Hematology, Children's Hospital Oakland, California, USA)</AU>
<TI>Query about your paper on "Femoral Head Osteonecrosis in Sickle Cell Disease"</TI>
<SO>Email message to: Lynne Neumayr</SO>
<YR>10th December 2009 [cited 14th December 2009]</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pande-1998" NAME="Pande 1998" TYPE="JOURNAL_ARTICLE">
<AU>Pande KC, Pand S, Babhulkar SS</AU>
<TI>Osteonecrosis of humeral head in sickle cell haemoglobinopathy</TI>
<SO>Journal of Bone and Joint Surgery (Br)</SO>
<YR>1998</YR>
<VL>80-B (1S)</VL>
<NO>Suppl I</NO>
<PG>73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pauling-1949" NAME="Pauling 1949" TYPE="JOURNAL_ARTICLE">
<AU>Pauling L, Itano HA, Singer SJ, Wells IC</AU>
<TI>Sickle cell anemia, a molecular disease</TI>
<SO>Science</SO>
<YR>1949</YR>
<VL>110</VL>
<PG>543-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Plancher-1997" NAME="Plancher 1997" TYPE="JOURNAL_ARTICLE">
<AU>Plancher KD, Razi A</AU>
<TI>Management of osteonecrosis of the femoral head</TI>
<SO>The Orthopedic Clinics of North America</SO>
<YR>1997</YR>
<VL>28</VL>
<NO>3</NO>
<PG>461-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Powars-2002" NAME="Powars 2002" TYPE="JOURNAL_ARTICLE">
<AU>Powars DR, Hiti A, Ramicone E, Johnson C, Chan L</AU>
<TI>Outcome in hemoglobin SC disease: a four-decade observational study of clinical, hematologic, and genetic factors</TI>
<SO>American Journal of Hematology</SO>
<YR>2002</YR>
<VL>70</VL>
<NO>3</NO>
<PG>206-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2012-02-27 04:42:46 +0000" MODIFIED_BY="Tracey Remmington" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<MD>CD-ROM and internet</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sadat_x002d_Ali-1994" NAME="Sadat-Ali 1994" TYPE="JOURNAL_ARTICLE">
<AU>Sadat-Ali M, Ammar A, Corea JR, Ibrahim AW</AU>
<TI>The spine in sickle cell disease</TI>
<SO>International Orthopaedics</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>3</NO>
<PG>154-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sathappan-2006" MODIFIED="2009-03-27 10:11:37 +0000" MODIFIED_BY="Tracey Remmington" NAME="Sathappan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sathappan SS, Ginat D, Di Cesare PE</AU>
<TI>Multidisciplinary management of orthopedic patients with sickle cell disease</TI>
<SO>Orthopedics</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>12</NO>
<PG>1094-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saunthararajah-2004" NAME="Saunthararajah 2004" TYPE="BOOK_SECTION">
<AU>Saunthararajah Y, Vichinsky EP, Embury SH</AU>
<TI>Sickle cell disease</TI>
<SO>Hoffman: Hematology: Basic Principles and Practice</SO>
<YR>2004</YR>
<PB>Churchill Livingstone</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Serjeant-1992" NAME="Serjeant 1992" TYPE="BOOK">
<AU>Serjeant GR</AU>
<SO>Sickle Cell Disease</SO>
<YR>1992</YR>
<EN>2nd</EN>
<PB>Oxford University Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Serjeant-2001" MODIFIED="2009-03-27 10:12:13 +0000" MODIFIED_BY="Tracey Remmington" NAME="Serjeant 2001" TYPE="JOURNAL_ARTICLE">
<AU>Serjeant GR</AU>
<TI>The emerging understanding of sickle cell disease</TI>
<SO>British Journal of Haematology</SO>
<YR>2001</YR>
<VL>112</VL>
<NO>1</NO>
<PG>3-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steinberg-2006" MODIFIED="2009-03-27 10:12:33 +0000" MODIFIED_BY="Tracey Remmington" NAME="Steinberg 2006" TYPE="JOURNAL_ARTICLE">
<AU>Steinberg MH</AU>
<TI>Pathophysiologically based drug treatment of sickle cell disease</TI>
<SO>Trends in Pharmacological Sciences</SO>
<YR>2006</YR>
<VL>27</VL>
<NO>4</NO>
<PG>204-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stuart-2004" MODIFIED="2009-03-27 10:13:07 +0000" MODIFIED_BY="Tracey Remmington" NAME="Stuart 2004" TYPE="JOURNAL_ARTICLE">
<AU>Stuart MJ, Nagel RL</AU>
<TI>Sickle-cell disease</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>364</VL>
<NO>9442</NO>
<PG>1343-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vichinsky-1999" MODIFIED="2009-03-27 10:13:16 +0000" MODIFIED_BY="Tracey Remmington" NAME="Vichinsky 1999" TYPE="JOURNAL_ARTICLE">
<AU>Vichinsky EP, Neumayr LD, Haberkern C, Earles AN, Eckman J, Koshy M et al</AU>
<TI>The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National Sickle Cell Surgery Study Group</TI>
<SO>American Journal of Hematology</SO>
<YR>1999</YR>
<VL>62</VL>
<NO>3</NO>
<PG>129-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weatherall-2006" NAME="Weatherall 2006" TYPE="BOOK_SECTION">
<AU>Weatherall D, Akinyanju O, Fucharoen S, Olivieri N, Musgrove P</AU>
<TI>Inherited Disorders of Hemoglobin</TI>
<SO>Disease Control Priorities in Developing Countries</SO>
<YR>2006</YR>
<PB>2nd edition. Washington (DC): The World Bank and Oxford University Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zavala-2006" MODIFIED="2009-03-27 10:13:27 +0000" MODIFIED_BY="Tracey Remmington" NAME="Zavala 2006" TYPE="COMPUTER_PROGRAM">
<AU>Zavala D, Martí A, Peña-Martí G, Comunián G</AU>
<TI>Sheet to enter data for performing a Cochrane review (www.cochrane.fcs.uc.edu.ve/hrs/)</TI>
<YR>2006</YR>
<PB>Valencia, Venezuela: Universidad de Carabobo</PB>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-07-26 12:58:57 +0100" MODIFIED_BY="Tracey Remmington">
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2004" MODIFIED="2012-02-27 03:37:43 +0000" MODIFIED_BY="[Empty name]" NAME="Martí-Carvajal 2004" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal A, Dunlop R, Agreda-Perez L</AU>
<TI>Treatment for avascular necrosis of bone in people with sickle cell disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-02-27 03:37:43 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-02-27 03:37:43 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004344.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2009" MODIFIED="2016-07-21 15:43:31 +0100" MODIFIED_BY="Tracey Remmington" NAME="Martí-Carvajal 2009" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal AJ, Sola I, Agreda-Perez LH</AU>
<TI>Treatment for avascular necrosis of bone in people with sickle cell disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-02-27 03:41:14 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2012-02-27 03:41:14 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004344.pub3"/><IDENTIFIER TYPE="PUBMED" VALUE="19588352"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2014" MODIFIED="2016-07-26 12:58:57 +0100" MODIFIED_BY="Tracey Remmington" NAME="Martí-Carvajal 2014" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal AJ, Solà I, Agreda-Pérez LH</AU>
<TI>Treatment for avascular necrosis of bone in people with sickle cell disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2016-07-21 15:43:06 +0100" MODIFIED_BY="Tracey Remmington"><IDENTIFIER MODIFIED="2016-07-21 15:43:06 +0100" MODIFIED_BY="Tracey Remmington" TYPE="DOI" VALUE="10.1002/14651858.CD004344.pub5"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-06-30 11:25:30 +0100" MODIFIED_BY="Tracey Remmington">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-06-30 11:25:30 +0100" MODIFIED_BY="Tracey Remmington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-06-30 11:25:30 +0100" MODIFIED_BY="Tracey Remmington" STUDY_ID="STD-NOTSCA--2006">
<CHAR_METHODS MODIFIED="2016-06-30 11:17:48 +0100" MODIFIED_BY="Tracey Remmington">
<P>Randomized, open-label, controlled study.<BR/>Trial type: multicentre study (15 centres). National: USA<BR/>Trial phase: III<BR/>Follow-up period: 3 years (mean).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-06-30 11:18:08 +0100" MODIFIED_BY="Tracey Remmington">
<P>Intervention: 17 (analysed: 17).</P>
<P>Control: 21 (analysed: 21).<BR/>Gender: women: 53% (9/17) / control group: 48% (10/21) / total: 50% (19/38).<BR/>Age: experimental group: 24.67 (mean) SD: not reported; control group: 26.41 (mean) SD: not reported; total group: 25.63 (mean) SD: not provided.</P>
<P>
<B>Inclusion criteria</B>
<BR/>People with hemoglobin-SS, hemoglobin-SC, or hemoglobin-S/ß-thalassemia who were ten years of age or older and had hip pain and/or a decreased range of motion of the hip were screened with plain radiographs and magnetic resonance images of both hips. Those with at least one hip with Stage-I, II, or III osteonecrosis of the femoral head, as defined by Steinberg et al. were eligible for enrolment.</P>
<P>
<B>Exclusion criteria</B>
<BR/>Steinberg stage IV.<BR/>Participants who were less than 10 years of age.<BR/>Concurrent condition other than SCD that predisposed them to the development of osteonecrosis of the femoral head (history of chronic systemic steroid use or alcoholism).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-06-30 11:18:17 +0100" MODIFIED_BY="Tracey Remmington">
<P>Experimental group: hip core decompression and physical therapy (17 hips).<BR/>Control group: physical therapy alone. After discharge, participants followed a standardized 6-week protocol of limited weight-bearing, physical therapy, and home exercises In the first 6 weeks. Physical therapy included outpatient visits and a home program of stretching and strengthening of the hip muscles, especially the adductors. Physical therapy continued for an additional 3 months after the initial 6-week period.<BR/>Co-interventions: transfusion, and hydration (surgical group).<BR/>Duration of treatment: 6 week for physical therapy. An additional 3 months after the initial 6-week period.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-06-30 11:25:30 +0100" MODIFIED_BY="Tracey Remmington">
<P>
<B>Primary outcomes</B>
<BR/>Clinical success: improvement in the baseline The Children&#8217;s Hospital Oakland Hip Evaluation Scale (CHOHES) score of at least 15 points at the time of follow up.<BR/>
<B>Secondary outcomes</B>
<BR/>1. Hip survival (an additional surgical intervention on the study hip (total hip replacement for participants treated in the surgical arm or hip core decompression or total hip replacement for those treated with physical therapy alone).<BR/>2. Complications<BR/>a. related to contralateral hips<BR/>b. related to SCD.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-12-18 15:02:29 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AVN: avascular necrosis<BR/>RCT: randomized controlled trial<BR/>SCD: sickle cell disease</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-03-07 14:11:32 +0000" MODIFIED_BY="Nikki Jahnke" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Al-Momen-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>People with AVN were not included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-02 14:20:31 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Al_x002d_Mousawi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-02 14:20:31 +0000" MODIFIED_BY="Nikki Jahnke">
<P>A narrative review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barnes-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>People with AVN were not included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eke-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>People with AVN were not included.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-02 14:23:54 +0000" MODIFIED_BY="Nikki Jahnke" STUDY_ID="STD-Mukisi_x002d_Mukasa-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-02 14:23:54 +0000" MODIFIED_BY="Nikki Jahnke">
<P>Not an RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Opio-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>People with AVN were not included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>AVN: avascular necrosis<BR/>RCT: randomized controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-06-20 10:16:12 +0100" MODIFIED_BY="Tracey Remmington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-06-30 11:20:46 +0100" MODIFIED_BY="Tracey Remmington">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-06-30 11:16:01 +0100" MODIFIED_BY="Tracey Remmington" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-30 11:16:01 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-NOTSCA--2006">
<DESCRIPTION>
<P>Study authors confirmed that participants were randomized by stage of AVN (I, II, III) to either the surgical or conservative-therapy arm.</P>
<P>A list of random numbers was generated for each stage of AVN. This stratified assignment aimed to ensure equal numbers of participants with Stage I, Stage II and Stage III in each of the treatment arms. Participating centers called the co-ordinating center for arm assignment.</P>
<P>If the initial work-up revealed AVN of the contralateral hip, the most symptomatic hip was randomized. The participant was randomized to surgery or conservative therapy based on the stage of the symptomatic hip.  </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-06-30 11:15:27 +0100" MODIFIED_BY="Tracey Remmington" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-30 11:15:27 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-NOTSCA--2006">
<DESCRIPTION>
<P>After radiologic staging and informed consent was obtained, participating centers called the co-ordinating center for arm assignment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-06-30 11:15:19 +0100" MODIFIED_BY="Tracey Remmington" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>Masking of patients</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.05" NO="5">
<NAME>Masking of outcome assessor</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Masking of caregivers</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.04" NO="4">
<NAME>Masking of physician</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2009-02-14 17:16:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-NOTSCA--2006">
<DESCRIPTION>
<P>Given the treatment options it was not possible to blind caregivers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2009-02-14 17:16:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-NOTSCA--2006">
<DESCRIPTION>
<P>Given the treatment options it was not possible to blind study participants.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.04" MODIFIED="2009-02-14 17:17:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-NOTSCA--2006">
<DESCRIPTION>
<P>Given the treatment options it was not possible to blind investigators or study participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.05" MODIFIED="2016-06-30 11:15:19 +0100" MODIFIED_BY="Tracey Remmington" RESULT="YES" STUDY_ID="STD-NOTSCA--2006">
<DESCRIPTION>
<P>Adequate.</P>
<P>The co-ordinating center&#8217;s radiology committee (3 radiologists) were blinded to the reports from the participating centers.</P>
<P>This information was confirmed by the study authors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="GROUP" NO="12">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="GROUP" NO="13">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-06-30 11:20:42 +0100" MODIFIED_BY="Tracey Remmington" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-06-30 11:20:42 +0100" MODIFIED_BY="Tracey Remmington" RESULT="NO" STUDY_ID="STD-NOTSCA--2006">
<DESCRIPTION>
<P>Inadequate.<BR/>Comment: there were post-randomization dropouts.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-02-14 16:34:59 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-02-14 16:34:59 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-NOTSCA--2006">
<DESCRIPTION>
<P>Inadequate.</P>
<P>This RCT did not report clinical important outcomes such as death and quality of life.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-07-03 12:55:21 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-07-03 12:55:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NOTSCA--2006">
<DESCRIPTION>
<P>Funding bias.</P>
<P>Adequate.</P>
<P>Comments: National Institutes of Health Grants 5-P60-HL20985 and M01-RR00046.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2016-06-30 11:20:46 +0100" MODIFIED_BY="Tracey Remmington" NO="7">
<NAME>Free of baseline imbalance?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-30 11:20:46 +0100" MODIFIED_BY="Tracey Remmington" RESULT="NO" STUDY_ID="STD-NOTSCA--2006">
<DESCRIPTION>
<P>Inadequate.</P>
<P>Comment: the table of baseline characteristics of study participants did not report all randomized individuals (N = 41). There was 19.5% (8/41) dropout after randomization (6 in the experimental group and 2 in the control group).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2009-12-14 13:58:21 +0000" MODIFIED_BY="Nikki Jahnke" NO="8">
<NAME>Free of academic bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-04-21 16:02:07 +0100" MODIFIED_BY="Nikki Jahnke" RESULT="NO" STUDY_ID="STD-NOTSCA--2006">
<DESCRIPTION>
<P>Inadequate.</P>
<P>This RCT was underpowered (power = 65%).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2016-06-30 11:19:10 +0100" MODIFIED_BY="Tracey Remmington" NO="9">
<NAME>Free attrition bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-30 11:19:10 +0100" MODIFIED_BY="Tracey Remmington" RESULT="NO" STUDY_ID="STD-NOTSCA--2006">
<DESCRIPTION>
<P>Inadequate.</P>
<P>Comments: there was 19.5% (8/41) drop out after randomization (6 of the experimental group and 2 of the control group).</P>
<P>After randomization, 8 participants (6 in Arm A (hip core decompression and physical therapy) and 2 in Arm B (physical therapy alone)) were withdrawn from the study; 6 of them were withdrawn because the parents or participant declined to participate and 2 were withdrawn at the discretion of the principal investigator.<BR/>This left 38 participants (38 hips; 17 in Arm A and 21 in Arm B) who completed the treatment protocol.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2016-06-30 11:14:19 +0100" MODIFIED_BY="Tracey Remmington" NO="10">
<NAME>Free of early stopping bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-06-30 11:14:19 +0100" MODIFIED_BY="Tracey Remmington" RESULT="UNKNOWN" STUDY_ID="STD-NOTSCA--2006">
<DESCRIPTION>
<P>Study duration was not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2009-12-28 17:12:17 +0000" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Free of retrospective selection bias?</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-28 17:12:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-NOTSCA--2006">
<DESCRIPTION>
<P>Participants were graded at the local center according to Steinberg stage. Due to variation in interpretation of the Steinberg staging system trial investigators included an expert panel to examine these grades and in some cases re-graded the stages. The panel were blind to the randomization and read the baseline films in a few batches at the end of the study. Consistency and reliability on the staging was important for analysis, especially since Stage IV was an exclusion criteria and below Stage IV was eligible for inclusion; the investigators confirmed that none of the study hips were Stage IV.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2016-06-30 11:21:49 +0100" MODIFIED_BY="Tracey Remmington">
<SOF_TABLE ID="SOF-01" MODIFIED="2016-06-30 11:21:49 +0100" MODIFIED_BY="Tracey Remmington" NO="1" READONLY="YES">
<TITLE MODIFIED="2009-03-27 20:38:18 +0000" MODIFIED_BY="Grade Profiler">Summary of findings</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TD COLSPAN="7">
<P>
<B>Treatment for avascular necrosis of bone in people with sickle cell disease</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population</B>: patients with Avascular necrosis in people with sickle cell disease</P>
<P>
<B>Settings</B>: hospital</P>
<P>
<B>Intervention</B>: hip core decompression and physical therapy</P>
<P>
<B>Comparison</B>: physical therapy alone</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="2" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Physical therapy alone </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Hip core decompression and physical therapy</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Pain</B>
<BR/>(follow up: 4 years)</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>619 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>588 per 1000</B>
<BR/>(347 to 990)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.95 </B>
<BR/>(0.56 to 1.6)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>38<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>Vaso-occlusive crisis</B>
<BR/>(follow up: 4 years)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>
<B>RR 1.14 </B>
<BR/>(0.72 to 1.8)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>38<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="6" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>619 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>706 per 1000</B>
<BR/>(446 to 1114)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Acute chest syndrome</B>
<BR/>(follow up: 4 years)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.06 </B>
<BR/>(0.44 to 2.56)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>38<BR/>(1)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>333 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>353 per 1000</B>
<BR/>(147 to 852)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Low risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: confidence interval; RR: risk ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality</B>: further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality</B>: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality</B>: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality</B>: we are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> 46x (46/176; 26%) of the eligible participants were enrolled in the study. After randomization, 8 participants (6 in intervention group and 2 in control group) withdrew from the study; 6 of them because the parents or the individual themselves, declined to participate and two were withdrawn at the discretion of the main investigator. Therefore, 38 participants (38 hips; 17 in Intervention group and 21 in control group) completed the treatment protocol.</P>
<P>
<SUP>2</SUP> There were few participants and few events. Therefore, the confidence intervals were wide.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-06-13 09:19:26 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-06-13 09:19:26 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Children&#8217;s Hospital Oakland Hip Evaluation Scale</TITLE>
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>CHOHES website</P>
</TH>
</TR>
<TR>
<TD>
<P>
<A HREF="http://www.ejbjs.org/cgi/data/88/12/2573/DC1/1">www.ejbjs.org/cgi/data/88/12/2573/DC1/1</A>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2014-06-13 09:18:46 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-07-30 18:18:15 +0100" MODIFIED_BY="[Empty name]">Steinberg system</TITLE>
<TABLE COLS="2" ROWS="6">
<TR>
<TH>
<P>Stage</P>
</TH>
<TH>
<P>Definition</P>
</TH>
</TR>
<TR>
<TD>
<P>0</P>
</TD>
<TD>
<P>No radiographic evidence of osteonecrosis osteonecrosis of the femoral head.</P>
</TD>
</TR>
<TR>
<TD>
<P>I</P>
</TD>
<TD>
<P>Osteonecrosis of the femoral head on magnetic resonance imaging but normal findings on plain radiographs.</P>
</TD>
</TR>
<TR>
<TD>
<P>II</P>
</TD>
<TD>
<P>Sclerosis and lucencies of the femoral head seen on plain radiographs.</P>
</TD>
</TR>
<TR>
<TD>
<P>III</P>
</TD>
<TD>
<P>Evidence of flattening of the femoral head on plain radiographs.</P>
</TD>
</TR>
<TR>
<TD>
<P>IV</P>
</TD>
<TD>
<P>Collapse of the femoral head with degenerative changes in the joint space.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-03-27 09:44:52 +0000" MODIFIED_BY="Tracey Remmington">
<COMPARISON ID="CMP-001" MODIFIED="2009-03-27 09:44:52 +0000" MODIFIED_BY="Tracey Remmington" NO="1">
<NAME>Hip core decompression and physical therapy versus physical therapy alone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-03-27 09:41:25 +0000" MODIFIED_BY="Tracey Remmington" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Pain</NAME>
<GROUP_LABEL_1>HCD &amp; physical therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Physical therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HCD &amp; phy therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours physical therapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.598841456715751" CI_START="0.5647401195704819" EFFECT_SIZE="0.9502262443438914" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.20380540065228175" LOG_CI_START="-0.24815135855466472" LOG_EFFECT_SIZE="-0.02217297895119145" ORDER="20366" O_E="0.0" SE="0.2654816375801999" STUDY_ID="STD-NOTSCA--2006" TOTAL_1="17" TOTAL_2="21" VAR="0.07048049989226461" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-03-27 09:42:51 +0000" MODIFIED_BY="Tracey Remmington" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Vaso-occlusive crisis</NAME>
<GROUP_LABEL_1>HCD &amp; physical therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Physical therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HCD &amp; phy therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours physical therapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7966702367506595" CI_START="0.7236826500699107" EFFECT_SIZE="1.1402714932126696" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="13" LOG_CI_END="0.25446837343529755" LOG_CI_START="-0.14045183924243085" LOG_EFFECT_SIZE="0.05700826709643338" ORDER="4" O_E="0.0" SE="0.23197808781347845" STUDY_ID="STD-NOTSCA--2006" TOTAL_1="17" TOTAL_2="21" VAR="0.05381383322559792" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-03-27 09:44:52 +0000" MODIFIED_BY="Tracey Remmington" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.68200978156727" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="21" WEIGHT="0.0" Z="0.0">
<NAME>Acute chest syndrome</NAME>
<GROUP_LABEL_1>HCD &amp; physical therapy</GROUP_LABEL_1>
<GROUP_LABEL_2>Physical therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours HCD &amp; phy therapy</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours physical therapy</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.5610237268356264" CI_START="0.4377574696745251" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.40841360204752075" LOG_CI_START="-0.35876643459745655" LOG_EFFECT_SIZE="0.024823583725032145" ORDER="5" O_E="0.0" SE="0.450645351127688" STUDY_ID="STD-NOTSCA--2006" TOTAL_1="17" TOTAL_2="21" VAR="0.2030812324929972" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-06-30 11:20:47 +0100" MODIFIED_BY="Tracey Remmington">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-06-30 11:20:47 +0100" MODIFIED_BY="Tracey Remmington" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgments about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAhAAAAHkCAIAAADgiYFMAAAaCElEQVR42u3dv45kRxWA8ZYsIYIN
Ntgn4Bk2QiMiiHgnNpzAEg73LSweAWEIjSMyBOwivIGDsZ2BWRWzHmnV9Nz+MzN1zr2n6vdpglZj
jtt1q85Xp27dW7sdAAAX0gAAOAlhAAAIAwBAGAAAwgAAEAYAgDAAAIQBAABhAAAIA3jEeNAIAGEA
nAEQBtB3PHhxDkAYAADCAAAQBpA/JKxHAYQBnB4PZ78BCAMAYQCEARAGQBhAyJBwDwMgDAAAYQAA
CANIHBL7Y0ODAIQBnLHFwQcAhAEQBkAYAGEAhAGEDgm2AAgDAEAYAADCADKHxP7Y0CAAYQBnbHHw
AQBhAIQBEAZAGABhAKFDgi0AwgAAEAYAgDCA7CHx46AwNADCAI6Oh2MfABAGQBgAYQCEARAGEDsk
doYGQBgAAMIAABAGkDck9seGBgEIAzhji4MPAAgDIAyAMADCAAgDCB0SbAEQBgCAMAAAhAFkDon9
saFBAMIAztji4AMAwgAIAyAMgDAAwgBChwRbAIQBACAMAABhANlDwhlKAGFgsRPs9wZN8fGDoQEQ
Bo6myMmzpNYACANSpNYACANSZFiDGBoAYWChE7AFAMLAuB3XXiaAMJDZA/xmAISBMfOvHgsQBtbr
AdWWd3RagDCAlSW3H9DQAAgDOFO42DYGEAbMqQkDIAzMlCKDlqQIAyAMrJMig56aDn1FoMc7AMJA
tjAqRgZAGFhhTk0YAGEA66f1uFcEeukIQBg41QMSgnseECAMDNQPpu8JWgAgDKxQcNyP8/TIH7dF
hT7prRsAhIGkCmN3nEJNoeoCCANRJcUAU3VjASAMDNhxI7K8sQAQBo4mx5w3vwa9wIMzAMLAaEVA
dOTQuy8uJUAYqCqM5o1PAGFgtR6QtXYEgDAwSCnQ8cHsMbbV6h4AYeBoEbDlk5Sib9SH3k4HCAOE
MX5rACAMtHZkEaZLryh3+CthAISBNZNv6debu44AYaCwMBygBBAGVu0EvReOCAMgDKgDHqyiKoe/
trC3VAGEAcJYs+OG2oIzAMLACMKIbg3CAAgDxztBv4WjhMfros8ht0sKIAwM6DlNARAGknpAWuS4
o/361kY57QMQBjgj6Uzv+zGfEr/0OeQAYSCxB5R6t7lzyAHCAAAQBpQvRU4LtyQFEAZWSL77H0If
r4trGd0DIAzkpfW4d0lxBkAYWE0YrcgrAhUZAGFgHGG0gFMroje/uoEBEAZS0zoAwgAAEAYQ170i
H/N2RCtAGEjtBIufO4btG7xiZIAwMJQtpHXCAAgD66TIuONOy1VFAGFgoE4Q//aOXv+K0M217mEA
hAEAIAwAAGEAAAgD6197kRMiA4SBQYQRcfVFBggDg17++L1Gk0cGCAPj1BkiR0cGCAMAQBiYrRN4
RWBwZIAwUL4HnP1GZACEAWmdMADCgLROGABhIKQTuNMQHBkgDAAAYQAAQBgAAMIAABAGAIAwsGYP
8JbA4MgAYWCQTnD/c6/8KzJAGBjQFvvfPL1XiAwQBghDZIAwMHMn+P/1+ohbApNHBggDAEAYAAAQ
Bg47QcAuUpEBwsBQPUDkhMgAYYAwRAYIA5whMgDCwGEPCFi1FxkgDAAAYQAAQBi4f+1bzCKMyABh
AAAIA3PXGae/ERkAYeD/cmL3ziAyQBgYsx+ITBUAYeABM2uRm5UogDCwcO1jdhyJDBAGAIAwAAAg
DJzuBPu9QeSgyABhYBxbHHwQubn7DRAGpHXCAAgD0jphAISByE4QkR9FBggDAEAYAAAQBk51goBn
m0UGCAND9YD9D30zr8gAYWBYYTS7pGIiA4QBwhAZIAxM6Qwv8PBqEIAwAACEAQAgDIRfe8ccBUcG
CAPjXH6RoyMDhIEBSw2R1RYAYUBloOYACAPqABUGQBhQT6gnAMLAhgoLe5nskgIIAwBAGAAAwgAA
EAYAgDAAAISBgXvA2W9EBkAYAADCAAAQBkI6QcBzaiIDhIFB0s3ij+z44LTIAGFghHRz+oc95WeL
DBAGpBsAhAG2C6iHRAYIA+Okm/0f3LceEhkgDAyVbqR1wgAIgzCkdcIACIMwAjpBxA8WGSAMSDcA
CAMAAMLAqU4Q8IC6yABhYJx0c7CA1jfzigwQBsZJN/Yy5UQGCAPl0420ThgAYRDGY362F3h4NQhA
GOWTLwAQBgCAMLD5Ymi3hMi21QKEUS/5AgBhAAAIAxU7QUBJJDJAGBgn3SyeQy5y98gAYaB8upHW
CQMgDMJ4zM8OeghOZIAwUDjd7I4jstsYAGHUS74AQBgAAMIAABAGAIAwAAAgDJztBE7eDo4MEAZq
p5u4XygyQBgYKt1I64QBEAZhyOycARAGZ3TvAQHLaCIDhAHpBgBhAABAGLiwMBJZgQgQRu3kG/eD
z34jMgDCKJN8CWMAYahdQBggDJEvGmaXfAkQBmFsen4qcmjk00GMPhDG9A0a8HCA+SkAwoD56VyX
0qADYaBk/go6H1vkE7YgexCG5Bv7pLf56TDlBWGAMFAy3djLlByZMEAYqJdudscROe5oJrYAYWjH
2HSTWWHE6XPmyABhIC/dmJ8CIAxsyHPdH4IT+UQZqu+BMCTfjIIjripyazo08scNdQYLCIMtQtJN
3PxUWl9FGJwBwtCaJeen3viUEJkwQBiQbvCYi+jygTCQkWsIAwBhYJ356X49JHJcZIAwUDvdJDwS
OHnkhPeMAYRRuwjom8gIo3pkYMXJK2HMknzrvnZbZGD1XNQiNvdr35nTjc2v1SMDJ4TR9m58PrHj
6btlki9GGsBqFyT3NxUGFW06kYlMGFg9YxCG+UKfdOPUipzIi5fMoEPhaauG2Hi6yZz5brwoLhc5
QUUAYcD8FECfvNGzENes09YuzfPYWZGBFW3RZa5JGFH5vXnSW2SAMDBSupHWBxCGWyMgDJeHMAjj
ogF8yZeYec2jV2cmjNmF0Tw1vVLkXq+Nedz/ChCGxQFsfTIBEAayVeSqEcZiaatjIC5vSD3zphvP
Y+dEjnaGnV24sG+4h7HpK7T9XHM/ePdVe5FPCIkwkCmMZpfU2Jcnc37a/V8k8gC9DjISYdQbumO8
pYow4joeWyBhzYMwzPVsfi0fGUjNFRrCXA85k4latQtAGJUvlfkpYZzrG7oHPm6Lsq22RjromxrM
TwnjbGRv2IUKo1hTXvIlYagRI7bPWQsFYUgKhAHCwCYyEmHMqyLPY+dETnaG4Yy4iSZhwPPYsZGD
bj8ChIHyXUpkYNTpIGHUuN6e9BZZ7YIHZ3bbahHdt0Sucq8IWCdXaIg4sVsqgesFwkBGUjA/xYr1
FkAY9WaR0edhxD0+InLdu1AAYVh5KC+5omJO+81GNAij3spA3MPeJc7yEzmzRmQLJFTMhGEWKf9W
jez+Ftbpclp2WmGErq2LnFN9AoQxQgFYIjIAziCMceoA6BvA6nUtYUgKNr/GRnanAaMZSENsXxj7
WSbu+B2RoyMDhIHl6WRQImthB3yKHB25u0LKlS8KrLoZyZUrVrtIvuUiJyxJLT6Hsc1x7ZGR0mse
hDG7MFrkeW0iJyTHY0lh+8LYb2RZiDCmuzDRs0j3SzGYMEAYAM4rP3oysdlxLees2Ov6RNOs2/Q5
xusbVmCwmNAr/VqXrfvk0S5+nBAGZ6AV3AIg9cRWGECCMCpOJoKeKyqdMTo2SNBdVcKAvUy1I5c+
w2Pyeqvi8TmEETJvirux2SKfbW6ew6iWyAhjgIyR1jdUGNsdBtK6yGcjdPnldc95JIy0maslqYmG
gcilIy+Osl5Dr+iGCDs4KlafrtbswjjIXBFvzxdZisTlA7zAe8BcsO1feOkGMNF8SpHhwT1g9kRT
d0mqYyIjjLON3CUyYUSNgVo/2zFHCZERl8gIgzA442ivchhRuciSL2GcTcQRTeFdUpWm6nYciZzc
3+ySQvhV0xCKVpFbzRd4GL8gDKQmsvt1scjllv4w0uJE98jNLqktX/hW5/kADKN8KXKAvrHlN0QQ
RpmkAH3jwszr/Vf6BmFMeuHj3kQUt4tf5LPdw6Yg6YIwXPh6byICOGNTqcO22rkufNDKgAXfwfJj
9JnehYaJLl0sv2kInaCW5ApFjn5awkNwIAyUn/mKnJPECaP66Au6J+c8jHqz9Zlf0iBy9StopIAw
UoduuZ8d9BCcyC3xhYmFulzfJw+4hzAII2oWGbe2LnJaiqw+UoI2oFc8szb6nlzzpPcMzij9gjmE
pkitcWLoBb1wocp0MKidpZ7w5L7x2gUDCKPiTKL7kwd1xwhhAAhPkdHppuiMrbozvEsKIeWLNgFh
jLcmseUNEVJPVA9oXmGN4vPToikS4ZdPQ2yzAMzJAtGvZJ88csL+Kyn42DCU3AhjRmHEOcO5eKtc
QYOu4hikT8Iok3ydFj5GZM441qUJY/sZiTBih8HkkhM5RxhxC3Q5vW7L+4IIgzCQJDmREyJXTJEJ
T6UUskXcLSjCkNa9WAKEMexFbJHHr7mHYaYAva5k37CXadEW+99ssFkIo8ZMoejuHZFXmakYg2Mc
MUAYZgqbE4ZTK3IiY5V6q7TyCYMwNjeLlNarC6Pu25NsAah61TTEbDOFnAUNkRcjt8hltNJTK8Ig
DAAlH+qsKIxW83Z6wssHm11SM9curhphjNEgmiLhpE7PYehSlWY3IiecMZfZZ/rWQ5NnIcJAvS4l
crKYO8a85MtJxkhRFVV5tShhzO4MaX37s/JVVIR1q65t9g09LOrat7BzGhJ21oqM/CypTcpcNQ2x
zQIwJz9mHuwzbWQpMs3KGvmgKQiDMCBFao2LIm+55XPuu/R9qR1hFBCGjCNFapDxhFGu4CCMGuVw
0aUSkWWuddu5+1pl6aZWYaBzVRT3Vp/JI7fIJzzK7SWN+HlxT3gkPGMYOvvp/zvlTcJwkGorexcq
7vidQsJI+7Xdt0EWWkYjjIyhu815k7Q+hjAKnaZQ1BnRPzVCGEG30wlj6xc+ucgIeouqyC39Nu/G
K4xya2j5NaIKgzAwb99IfppX3yvdN7rffenSKwgj9tqH9iqtDSBTQlJPsdql3EtHRMb9nhxdbwWV
+OVO2uj+Iw2JksJoNW/GzhxZ9blWiixxll+Vy0cY4ZUgYYjccs8hN7WqJYyc8webE/eGLwBzymGZ
PSEyYaw1aatY5W82MmGUEUa5qkjkVWaRiB4pEW0edN+FMDhDEeAexhnDGdHVZ2z93/7kAKUqF757
8CqTU5GR2Z9LH9Fa7KppiCp1QK0Xp4uM/P6cOSMkDMw1wJyLl1kj9tVS3Tl1RWFkPgu12UqOMLZe
aJeekeGEITwt0VKeaZh5W23330wYVYfB9ldgRE5OCrVUVLc/EwZhTF0HyOxpkUM3wLjN22o+C0UY
hFFpZdadhoTIRVMkZ5Sut5pttTNfeDlipCw2+ZPeXh9Z+KppiGnTDVap4aos3JcrAoJOC4+ua6tc
UMIgjDLlcOnIabdGJl9GK3daeMJkwpJUpctfLpFN+Eo1lRxnTNIUbnrP2A9K1C4iV68DKk6tKk7a
Co1uwpjdGdL6KhVGlQU65PSNnMMLLElNJIyK8yaRE/qGZbRhplY5L/55SscmjNhCe8uViqfq1k2y
cwoj50zviNfztPhTK7b//BZhTFep3B+6IodGzp9MeNK7b/KN3stEGCjjjJxjWyaPnFzaGiat5ovT
I35w37sjelhG/g2a42x8KUZkmK0Ppk/CCMw43jwosjpAvUUYuDTdcIbICX1DigRhEEZGUvBO2bTI
QX2j+nkYzUpgfDv36hiEUaMcthPGZGKkvlFxL1OLPMuvynAmDLULak8mWuU7Z0FnUwaV+GklF2Fg
u8IIfdBJ5GQPlbiZUfq407QLusFpCmEEXuxar92OG7oiI78/lysy7jdFl/ze9z+BMMoU2nXneiJj
DBWVu4dBGIRBGISRV9dijIxEGNMJI+7GpnfK5kQ2TTn2s6dNQU7c4wzbapFaB6hrz2bhaScTUX3Y
YJ6ttMQwKZIwTkQuephx3G8mDLWLyFPvRmuW0XIjR6TjKs4gjMCR4ExvkUvXAQkToLjMW+sJjyqv
uiGMGvMmwqgeuSXe35p5AtSCz8d2D4MwphZGC95/JfIq1lcVodlWSxhRU4asQ59mjlxxQSOuP1c8
2TBzGG6zJ7tUIRfedAwJEqo7AYrbyxRRI378kTli3vJyJWFMPQcJ6moiJwzd0hOgonuZrEwQRplx
G50OTn8pMmrVLt3HTtEddH0fFyWMqYWxWLuIHB25Wa4stZcp5wUeEa3hiFYDDObU6UsQbk3XHICE
MW9nNXQJI7l2Cb01DcKAGRmyhVH0LVVpi4q9NizkvFO2bftd1JLa7EUr1ppMUFHE2KlYFdklRRhl
0g3ULhcGr/Xm1wTJFVI+YczljOTnhEP3lswZuWLtkjZSCr0VuK7yCaPA0C33auW+XVbkVvlJ75wB
UmiLarmjmbwaZMbyoq3xOFLc25PmjBydgiP6G8mBMEoKo6Uf/koYVYRx0D0Mw3KTNsLQqwqvEnT8
DxE5QfkJBYdBbVGRMJI6lmZBwvw0qL9FbCsoOleLiF+uNSS1GomGiggjv6SI+M1xS3zRi4dagzCw
XBiJHH27aObz3svtig5dkqoVmTBik2+J+Wm5JYKikbsP4JxXVkQ0jr5RNDJhFChaQ2+4GQY5kasX
nRZCQRg1SvgWv2FX5LrOKLrdc4CzUiq+ipEwDN3+c0mRS9wdGeC08ISpVcWTtzfbGoRRdd7kqlWf
TExbEjUHqRIGcgaYo2wIQy1OGISB7M4at8dG5BWLjBI/uJW9h7H/r5iwNQgj5KrE7WWqdSI0TneS
jc9PdTMQRl6tXWV2g1UWYeIil9gCAMLQmpV2ScVVRSInT9XldBAGYYxTFYncLO+AMJA210u7sTnh
3o+cyBWXd/Z/qkQBwpi9dhF5jBoxIq1HnzUdpCKR4yITxuzCaEO8pKFE5Oi+Efd8gMgiE0bsXK/Q
22awSt8gDJEJQx0ApNaIOQtHJCcyYRBGalU0c+Sii4rl6i2RQyMTRhlnlH5fhchFb6cDhJE3Va+4
L0haLzenrlh9gjCQV7goMio6I2GCUu7p9Gbzq221qCIMxxzlRB6j13WP7NZ0c9NbyWZbLU7n30JL
UoQhMmFkzJs0LBJqxIgFjbqv6xeZMKoKo23+bbXNMUfxkaOFUfSsFFtUK0YmjK0LI3quh+opsuLR
oajdhzVExOjVsDBNuVBF3VtD5IjIhGHC65ij8pVcuYc65d+ikQlj3rSO1S+lprDlulZkqaf/GEib
o6FW96ie1l1E6Ar908H+fpvQy9ZXckFTG5FDhbH/Iwu9LRGEQRids/mFRUxHyfXKCyLnOCOnNfr+
J7gNUDoyYcQO3YiZb610I/LBRez+7EhdYZQ49F5kwqgkjLibItJ6coWR1usIQ2TCUGGoMAgj7zcH
3cOQfAkDSZtfE7bceQ6j1hMeB6G2/75LV7B0ZMIo7CftAGCFmbGGAAAQBgCAMAAAhAEAIAwAAGEM
31IAMDqE0UEYIossssgzRyYMXUpkkUUWmTBceJFFFllkwiAMkUUWWWTCIAyRRRZZZMIgDJFFFllk
wiCMmx9urt9cX3119fyPz3e/3z374tnLL1+++vurb/7zzWYj/3Bz8+b6+qurqz8+f/773e6LZ8++
fPny769e/eebGSNrZ62RH/n9+5tvv71+9+7q7dvn//jH7s2bZ19//fLm5tX791u8goTRRxiv//X6
xZ9e3F6V+3+3V+uzf362wcj/ev36Ty9eLAXe3Y6Kf342V2TtrDXyI3///eu3b1/ceuL+360/vvtu
c1eQMDoI41baixdm/+/2n9lU5NvJ0bnAu9t/ZpLI2llr5Ee+LSMWVbH/d/vPbOoKEsZThXFr8rPX
5u7vmNXzI9/OmC4LvDs2exopsnbWGvmRb2uLs7a4+ztWZ+RfwUuFcfawxvsPlJ943PzEA+gnHky/
xGqL//cnfnn6B9z8cHOs7lusBN/9+93qkX+4uTlWXy9W3P9+N3Jk7aw18iO/f3+zvxL1hz/sfvGL
3U9/+uHv17/e/fnPh2tT//3v+lfwYcK4n1vPfj6mlkfEueQ468X/+xO/PNuI12+uL7w2J8rA5Mhv
rq8fEni53B4msnbWGvmRv/32el8JP/vZhwT7u9/tPv/8w4ef//yihankK/jgCuNsnn2oIS6Pc4kw
zoa9/MvLK4yrr64WLsMdS5fn5ZcvV4/81dXVg4bBly9HjqydtUZ+5HfvrhZXn/761w8t/ZOfHH7/
9dfrX8FNCOPCFac0YTx0Sepuv9rll+fZF89Wj3y3L/Dyvy+ejRxZO2uN/Mh3O2gP/v7yl90vf/mh
pX/728P/6c2b9a/gY+5hnPhwuSEW72Gc/okPvZPxuHWq09XG8peLF2afe1do9cj3u82LM4FHjqyd
tUZ+5MXy4le/+hDzN79ZvvW9+hV85E3vg8n+I4Rx4ZLUsfvnccJ4xD0MFYY5tdbQ67pUGJ988qGZ
//a3BVtUrTCeLoxH3MN4UIVxyU31jsJwD8OqvdbQ63rdwzj2V/IexrFNU6G7pM4GPLv8ZZeU/Sra
WWtseZfU3d8dlz++t/VdUmcVcmGefdBzGJcL49jKlecwDrAjXjtrjXUjHzyHcVoY9Z7DQPOk97iR
tbPW8KQ3YSQJo3mXVP3I2llr5Ef2LqlJhXFn9eX9CT/WfZ++/XSDkW9nT8f2gdx+//bTuSJrZ62R
H/nHt9U+P/622s1dQcLoI4x2/O3zi6uEG4l87C3/i6uxw0fWzlojP/Kx8zAW71usfgUJo5swRBZZ
ZJHHjkwYupTIIossMmG48CKLLLLIhEEYIossssiEQRgiiyyyyIRBGCKLLLLIhDGDMABgBggDANBj
3qwhAACEAQAgDAAAYQAACAMAQBgAAMIAABAGAADn+R8ZiNYG2TK9YwAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-06-30 11:20:47 +0100" MODIFIED_BY="Tracey Remmington" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAs8AAAGvCAMAAACTsMhCAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAA4SUlEQVR42u19CXAc13nmj6OvmQFmpgdYEaKtEASiVC3XtQ5tSrwg
yUNSElbeUHbFFa6PtaRUQaIt2+tKaiNpyyuldksk5ShxlpYtUYpoy1YqKqmYUIpNWQRhSwMqazDm
JooYp2QcNGgClIjpAUDM9HT3DLDv6HMwAwIgeGDwfyTQ3e/9x3uv/3n9d0+/DwAIRPWgBuI4CIhq
QaYWxwBRRcB4RmA8IxAYzwgExjMCgfGMwHhGIDCeEYhrB/U4BMscGRwC33eCGM94iV32mMbBQOCH
G4HAeEYgMJ4RCIxnBMYzYsmgXXFFRLXEc5JAVPrKVl2tNq2u4FsNX6SF15dXTJaXjqgYt9U3P/f0
9JwTb72mmrSJtKrc7Pv7Zy6iuLm8otPTkuPhHM7nVZlvqENFgCZFkONkEovKQgrACov0y6K+kBQi
Jz35jLhNTUmSzsUlUSF7WkgKkzorJB1M8smP/FgRMWxRK50iEbE6xYNuGTDZZ4hQX1gMkStCMiaL
qmsnGZNIG0TShiT7R4VDvNz2u7ZRpb5lzze4tpo7JdVVDPvbwPwqzB/ppCxJpF+6KHSmQH1wLQZu
VebP7XUAWc0K5ejByOQ2gIR4jsZLUjLkG8i269zf5z85Oh5l0tmQqZA4vGHCeJ3ERkIe/YpnKZEx
xQTdefFYI0D8j6K7WZmU4LXCaBfZbPipmd5AttMjkaxrB14ZJW0wSRt6+Ewat31PO36tncx3yPNN
bZ0x09tJhP7DVNZRrBfMw/VuG5jfs6ENbGfqqDFOXEZ/bB3aAbDTwsCtunim+bPxJokIBbQt5HhI
VbYCGAPqCXJQGIB+etJPqMpGXkHjxVL7ycRXEKBDAdjVr/pefTAEyBjMSkcHgLn+fJ6VaQavHWKy
8k2gEE04rVKPth1Yr7ptYKC+C0zK9mutK/VNbamgmKRuUDAcRXkQ1stuGyjS6pjMdvIdQI3Vb9N1
0rB1GM+VUAfK8mx4a8/QC/Jr7eQS/rRQ++EhaH2AlA1B/ePwLNnc8gDsqytC6yPgVBC8/6QxNpyD
W1pbW39dhH95HOpIOa0iP7eSwuGiI3zrA1SelrX3s0/C47DPFjo97QjZduiR0wb2n/quLfr81j1O
fed9vj1b3BNXJPv76v2KrcMAf/gLemAl9r1JHLz/lEitUCkX+ZoVH8Qzbgznl3O+0fGxG9hDBfGt
wKMvmm8cJ5uOWel2bvTlSVJH7iTJzFijQZ/3tKyXF9roZTkuLXvdEaGyNaTAmxqPeyqBNsz23Ud9
n/P59mz1+m7tyL42E1BsBu0FttM43ThJe5Ad3US2fTM4EVdj/nzvDMlFp/+tf4NXJLXBGrJ5QoH2
n5eKK6pK5zLBAp1cxeU22E6DKKW10mu9BfGQKymetGRW1s3LpFbY3gvQ3Qeqdzmz7VCQNmx3PwZC
qW/xI8S37vg+yC3YtsQ2SyKK7FNitMNJI9DiHNwosp1iemeC92AX2XxExMCtyvvB/o0ahO9r8VHi
pE2J3lJtSoj5WU/A3tCFbBigJybGLwCMWSLt/LFkC92kY8JG7ymx8mTkKCt7kpelCxIVytwm6ZPe
YzRuhyJ0HzMiXsfKE6Ie8F1Pit9Qhew4qYuKu7kF25aiR7pJmEdY4m0IdxcCLQ516qfZzrEG5uCN
m8UoadF1+JZvJaxsfqRkz7xF37ozt1gv2kNPCUvZau2hvb5vVJASCKbdGM6s7HgWzXnecGxPCeOL
j8mDX5laylaHv30vYDxjPFcncL2Vb71VBjOxqjmXCMD36xAYzwgExjMCgfGMQCwEeD+43IHPN5BP
Bi+xVQXkk0HghxuBwHhGIDCeEQiMZwTGMw6BdvVNI/8AxvO8EU/StVDJijwz118aA81cuqv55q3I
RXRWL4hPZgZfQVrJ8Wz9/JU56+cmc7kkbOKz757MxeUWwCdT2Ijz+cqNZ80884x7/m3KFkuWVErS
Inb5yFwETuYiC5zMhctoIVHRXAoZuywsUsKYUUWUu/kEGhcltamL0sfYdVw+yafWtuMC6KIopwIU
NdwfsegS0QR9MSGFtcn1lRIkuQmE420YuCs2nttEtd49/wnRFBIAMaUhR0lazE0umUtCsET6ZenM
SA9ngeEycclUGDkMo5Cxy8bNn6wBuE8zlU/an5lz43lzL6WPoXVxR942bYoA0Yh5dAfAwxlTfJi3
JGRRspq43LDRI6Lx+2IlZ1/nhDbU110kshuMoxcARAMDd8XGsyXAYZdkwBiAQYNSvozlGUnLvS4L
zK5BGLgfKAtMB2eB4TKyTUxjU8iwMkWADhPgiAKZzVw5oyobOX2MYhPGcHk7P3gPQHhUX0dU9wuQ
2c/9nQdtF+WTGTviyAV9UQyrHbvYDvVFyiQztY40/70iBm4FVP16K20VibLec2qyB/h/umiQr4O1
mgsdhlNMiySDbXit99tWsIX4/VnKAm3NPQc2u7qOBK8LyAs0r4hZHf88xqp7TUfwuOF5CTbOc87b
ZPuiVt45H1z3iOsH/esHq34w2sWenh7BSTh6XboZgujMkeddueNayVMzLkOLa0rLOBXM6tofXpjl
7niAcsa+BhItIXvu4Sk/bQ0VNByLXhOCZEeW0ybbF7Hyi49DqRRiBeUbabos+7ATNXI7rJUB6tub
ye/C2Lon3SDNt0Nb3q/IZSg5jFBSluekMNNC/+y3E/MuYQxFijEw1ZMCWVelaU5bwyk9pGZGYCO0
NXU6ckFfFI1wSuIzEPclp9TXyG3hqToM3JUazyQpBViv2AE9ZHRZaYDx3AUSSxMNLc+RsidaWJJr
iGZgguYywwkpP1xSluGkMOGph2YTi2ei0m6PckZiqbj4PYCGuLjtGKWo6cpzyqWhnJgnTct85sIh
R244Ifp8UUw+eGea7di+Ii+JPyDW35UwcFdq/nwtpPCfe3VJ+WSs33sR+WQq5M8Yz1cA8aVNeGcS
/gsJxrM/nnF9yhVAZmnv32qCN67TOMC+ux4cguU++eMQrKT7QQTGMwKB8YxAYDwjEHg/iHCBfDLI
J1NVwJc5ZjDfQGD+jEBgPCMQGM8IBMYzAuN5hUK7yDFipcVzMpkUlVQZppZK1C3xPy5TmBIbF+U8
sJmfcGDvcyUyn1sQpUvEe+KpPEN+PSOXV5yjfbo4s5CWIy77/NzTc+612/nerKpyM2J+T5nSbccm
L6UJi9Y0Zh8vgNIlk3fn802/0ED76uYFty8aqbmc/cN4XgTU7UV3Ro52iilG2KLaBXFGi6IpcozP
Mm2CAElVUvpcWhWik9z6qI/KBZIxqeugLgvEUiokyjHPriIe9NOxgCXbVCu2nC5IShOraVZEyvri
+pfsubQvJMbAsUEJXIjfCLHRp3iULkSGts/WrexHoCts7cnzmXZoz3t+VUlUOCNNtLHsOHAfya0f
ZeZZv7y+ghaSKCGNFZbi7DonjxIZ6AuLId4un33EkufP8ZC3/+KxHwAkjpxz/qQ6p0V5SRqxXzin
tCpQGJU3EKmMeYQSpdS9SKlUEoctkR2NEKXRL3ypZWRyG8DtPzH5eWN2469Fd3t6BM+N2FQrttzX
IsYbn2YFfxA2w1nPvzJqs1VskM/RltQzG8zvsHWe2PiEdFp3KF02yCZtHxRHIlNz+hEfcydPtQDF
Y57fqZCpsU9QrDhZdhy4D4dDhvXL6Wvdi/DShJEm6onDdrP1fw//ToAN42Z6Oz0c8ewjljieSQL9
u14OOKR29JPL9n9QT7sFlBbllUGVL+mEje+RX2l1gKSahgC30At+P5sE8+thIG8fpdWOTYOMmUXv
YBQqtl1z/fm8p0fwMbWDL8e25f7aSq07wAq+PQbaFs9/v+Nf5nuya8NIgEL2Ng62uAu75X6g7aOU
Llvn9PPeq27HP7DA/C+eX8HSdaoRM4bLj4Pjg3/IWb+cvpIR+LoAColco9Eex+8R6xJtNG0qDKiu
fUQ5XML6Qcp2Mtqa95GhkB/JgGABpT7xaFXonmD5aFXKULnYP307ioXNPbOZXHpNxznXseWsuFHb
MMYu4c3W9KbK/oOULr3mLEoXwSpL6VLix6V0SfbIFyIGEbD99t1WhCmSWR2T6e8y7fD5cIqI7aLT
ZN4odxy16/Nk6vbR1Nj2vVQe39+YWTI+mZbp2c/B+oIXAJenhdKqUIaUOj+tCsUsKheGW2pEH10L
J8nw6TU7OracMPV+iKcI0ZmxSDn/dRpYUErpYs6mdAkOSQU//hWu9fX1Pr835UZDX6YzRai+/DgE
fHDnxLZzV2w3yh1HtS5eF6CpcewjLkP+3F26EF86CduDj6XWwpoUP+2nyK8EtJE02rDgLS/zzr8L
bbMZJWYCdC3CScrk4tPLOlQrtpysq6/yjLMwpvseXuhtsIbviW1AbxhlbqNdAynN8v8n2kdldgyM
0iXIKlPJz6knfPF8v+Dzq+hqzffYXBEaLTsOwimfD94vX1+/ZYGqkHFshe29vNm/e57R1Kg2TY1r
H7Hk+bP4e6GSsvTdUpC854Qp1XInf04z0lrJJHlhISbuCbsihU7RTM+yHv74qgPekfLkZCag9zPZ
oVrhcg1xkV+7YaLhM7UB/4f43mljGy1PxwRq469XQfq3xDzZ+1KuNcOO6fOxhGQEXyiu4GfrY97D
4df6X/P5DX9ayE7wS9Vvlx2HzB0+H7xfvr5+LCbm3iStLEh2Jz7o1RlNjW5fdDz7iCXNn+f/VC+f
Y6d39aSQrJIHqlbjWXWx4zDva9/O7HzEMH/258+XPZ4b8zW1kzwriVtTUpUwFwcpXRY4DvNyIE+L
4wLG8zUXz4jLDFxv5VtvhfxI1XMuEYDviyIwnhEIjGcEAuMZgVgI8H5wuQOfbyCfTFUBnz8jnwwC
82cEAuMZgcB4RiAwnhEYzzgEcI2Sy2jzLENchnhOJpMC5QuYP7lMOTaVq0Uu86ESmQ8tjFzGexVa
oU9C40p5xTnap0qzh+P6MhqrMWKv0Pzc0/O+zNfvzY9cRi+UC5irRC6zcfbxQshldI9chuxquU0L
bl92fPZT5M1lNDZhxF6xfEPN/Fd3Ro51dukAaY9cJtYlkgItJHfb5DKiAMm3bOqUrrBGReRkByWX
EcNpctQtkx9J0nWZ0sk0hbooLYxtd1SRdFePwlJs0hdbThfvfJAv1mt+kJPLOP6lbvvzFGI0M9of
ddnkMmnu15KJuE0uY1O7JGOSpM/lR8h55DL6u6DkPb+6JCi8Id3RsuOghUTiI7nlLjZyOm0N0ZW8
RqTd8SDjQEt0UbT7hpiNOlCWxE7rEEDsX/N0S/+fTWWPFmH6nTOPrrUL/v4b0SJ8t3744OgQ+xzJ
OWj9s9889VgNxDP/1PDnBrS+/+sHWnvgT97Jhr9FjtY8u681e7jzldjwN14qwq0n34nmio5d61So
pujoUee//uCO5repH1suHH539x+wC8D0exeiU0XH/95Gx//eZ5/9i+uHYO9b/zTZbAwRv9Pd0JB9
GxplJVugx8TYU9JU5EmT6P6G6s7hp9mwYIgPw3j47SalZcjxGw7lLrxcIBox+a2y4/DUtw8RH9Qh
1T7TfVvL27au3Qi7Xa3ZvyPjQMvC4azdN448fj/oxXB+yeZnkkCv93LA0+q9WwH2D6gZt4ByxJiD
qs1hV/TIZXYJoO0Ch1xm/wAM0iDdSY4ecclljiicI4bbfWbwvOHpEZxQO/azHVtOeCy1ky+hzo8B
Y4bh/pV+9RF7BHYyepf7BVC4jf3EGrFRGDjvrr22+mHAcnXn8POeF17nnwJT8PzWFzj5S7fxWPlx
sHZyH3bmoq7f77XZ3y4yFnYjRLdviNlYqvVWdKFr0wWjLJeMV+BQyoBLr0K29MJ73PATx4jmfMll
jhuOc67jkr6YNS65zC1GZf+e7wrkMr6mzOFHsNxh8MhlqN++2wqQnU0u47XD58M9sJoKdpuD7eIF
VsyqOd3iy95xfl46PpkAxr5YUnBPKVFMLad0AftvqluMWIVypXjLZNvLksvcWvNjH7lML5Pw6TWD
do9fTpg69yOXXObVcv5tehfPRnt5cplgsFTw46eg2Vf/hM/vTblzYcozUBOKlx+HoA+N2Q+0uT1A
vUN9Zs/9qBUn4ivw/Dn2YklB41qHy8WGtBYe5iwpjFzmYWjTGVeKj9axsR3WfnWW6aIgJ7wjsa1Z
CuhlQWn0y8m6KnHmpsJR3acovUx88vs2TjMjcRvkA9JI9jpJu9opvwv/wAiHoS24xLqCn8O+txRl
+VGf305VHWFZWKajuew4BH2sgbXEfqGb6faykLfb5XySLV/fEJcxnpNJwRovKdtjdQXJZboN6Tk+
G4k0GfwryeQkMfkBT8cQrNk80ZGpDp+lTP5T3QG9Cbl5j1+uIS5tO8Zrbmk55PP/dfk524Qp0/I0
tyGugj0xIf+PAOO5CyF2TDD8ZdHhVIQ5/dwjeo+K/8eWUZ/f53UxynlgHsmVHQfiI+/5qBMLxP7E
rUxXYIp2u5zJOUIJbey+IS5f/jz/p3o6e/alXX+heshlGkbUxY7DrJuQBQPzZ3/+vFTP6+aHxi++
W5xkE+2+nkPmSLFKrnGNf7rocQhgxy8W4R2f1/mf1yGfzHIHrrdCPpmqPJcIwPfrEBjPCATGMwKB
8YxALAR4P7jcgc83kE+mqoDPn5FPBoH5MwKB8YxAYDwjEBjPCIznFd37a5JHBnEV4zmZTEpK8wJ4
ZNRwuUJpZlHOA5v5CQf2ri+RuX5hPDLeG8yhGPkVD5VXnKN9AQKd5ByNTmKoXpn5uadnVP4U35tV
VW5G/P0zZUrL0aksoAmL1tw8+3gBPDLDcXc+35jXQNM3Lrh92y5CoNNz6X3EeF4g1Mz33RmZU6/0
hcSYXRDtpPwpVqgrzmeYtY0qJA+KIYvRtTg8Mlvugr6wGOpjR5CMS5J6UKZcNE33S5xHhtulZC+O
HoWlMB1XTheFTs61kuoUpZjnPywetDXCIuORYTYoPYvtt5nK2RQulNLGcnUr+1EfXOtOnHWHQanz
/OqiJPOGxBrLjgP3kdzKFhsm9W0KsQ8HJdJn2YI+hVyxREVn1q1O2nbqW/aPBeKy5c9x2d2dHh0n
Z3ND+py7YvPFY+SKmhD2OhG4k/z6yrlXEwA3TBiv09iqGekh088GyZST7IhE22g4/99GIlmAqc8b
41nX7ieU07qnR5A4G9rAdmy56I+tQztYwe2HzJDu+T987mu2hniOtoTbYH5/aqaJDf0fsjF2TGUE
k69wZbpz+NlpuROn9DW4TvT8NkaMyHY2NtZk2XFIiNSH7RCue1mm9r82Svosvwm3i5ANmQpfxFX/
R9Hd3PdRdyyiGLiXK55JAv27XrJwWlW2sGXPabtgSO3oADCGHGIZax0w2hQDoCBAB10oM8DOm9wP
/ZZ9lFG1jUMqJWzJd4Cy1bVbGGjRPT2ghDRj/LNky9Vv4/QtJD4VyGzx/K9XT3MNY0A9AX4b8k2g
kD1rUHA5E4xBWC+7unP4WecxwdQVoFjn+ZXM1HvUXjx/pvw4GAPch2OfEuuQXpI+v3Y3FOqg3lL7
+SwsrbcZbnxjsRUDtwIudf1ga8/Q0N+Yv3B4vh5gzF+1e6AuUFD3OOxrZfxWZA9ah2FffRFuaW1t
/XXREbn1AdhXO82PnJ8hsBL73vzwkE+GwNYDZgj+8Bc+ufe/Lf2ZyhZSa08LXefL+K9/HJ4le45v
YpPsnZ62TfNG06bUuw2bw8++OmcFZOupe49+kCICtt+sPPOFeA5az0w/Vld2HKiPHf2e/X3UPhM6
WHP+/Vf3vf+kMTac8zo9ayxc4PrBpeb7uvn7JQW3uHQpNmo06LN3+9iPw+Vi+kW02Y1pnG703TAd
d3lkbL1m0F7wy6m50We4/PU14l+U9a+V+K4he5bDuMFB9rXg85YKfvp8IvINss+vkN0booQ2U37a
EH87qA/vHs9y7LNzEpdV6uHlSUey3FggLl/+XLpS+UQbNAUKpFbYzvlTxI+QX9vhpMxIsg56F4ef
nyolb6Eopnf6AkJoH1UCejrcqPvlFFXdxSNxRuj3vToonYTt9t5a9nIhsaHLjJ6l2wKVWBPXWpJD
4WK0w0kj0IwKfj4ieiIvFL7v80syrlfZ3D1uWmXHIegjAW2eqYT8AvNgz7viyWa5zFggLlf+LBkT
JWWnDTloN12Q7ALhOpp0iHeTC2ZPVNz9pvfw63aphLyF4liDnw4mk2vVAnpKp57xy71xs0PfEp5a
5ePESN8t2Z+5tCXRoOiJifELjJ4lE5X0SUpRE+l2KFwKhnB3kJ26gp/r6r0Hw8Jmwee3QRVtMo1I
tOw4BH3USuZp96B/y3niQRey/Em98uTkUcc3fpt7MVwxvoK37uR57UN71WrhkaF9Wew4BOeEwICk
7sgtxCDyyfj5ZK5MPM9sTwnjPJs4+JUp0ayOYYzsv3fx4xBIxwLZzbb/p2E8X9vxjLh8wPVWyCdT
lecSAfi+KALjGYHAeEYgMJ4RiIUA7weXO/D5BvLJ4CW2qjCNg4HADzcCgfGMQGA8IxAYzwiM52rB
NckNgwQ1VzGek8mkGBpdADdMPFKmUPdTpMwfl8wNs7pEZvWCuGG8Vw5BobtxpbziHO3Tpe/OKluN
EXYV5+eennPifXyvVK4sN8zGcs/yoxOXsspt8a/6b5p9vABumMJGdyrdpGug5TYtuH3R8O6LNgpx
ZfMNdfyYOyNHFTEFYEUorwsni2EUL32KFOOzVNtxAZKqpGg+ChYlufUuciTwI8oNI3fpuiwQS6OK
KHd7dhWb6CVsL7CzFKbjyqUESearEJtksUt1/WuKZM+lWkjqBtZCSs1C/tl+LZlI2NwwREbhpDWS
Opcf4XibO/nq7dAueH5tahcasdGy46CFROIjufWjzHxEsO3bTbAcEhzWjrgkx1MS0w9JIc3fP9uP
3W+7L7oo0iNS16mzvnPSHQkjd375s5+D7ewEOSuJ+nPOOrdpRvGyQR61v48xf0R+pUfp9TkxbkoP
k6O6s5QipV6wRPrFY90IQHHkkNoy0rMN4D7NVO5y7calrE+Pej77Ov+y0pZLNhhHL7CCqaPmpqzr
/4bvjNosAXF59HWySWRM8WFGzZLoZ6sD43LDRoeqJS4Zyg1MN5yd049ouJOvWoCi4Pml1C6fpuWx
4kTZcYhLJvHhkNHU877bs3kPxJSGnNcObTRjfpLSxkDyZ0Y67u+f7cduT2Kc9SUaMY9Osbqfk7ob
FIOR7rwyipE7j3im3DDeQv0hVekA2DXoULFwuhOQB1Sb/aFAuWEKar8MYAig7SdH/WwSvH8QBu63
j9Lq2KZBtWMrwBGX4oXaNQeFvKdHMKx23M92jriULOv4OqR8B9y7xfVv7XTIapR+9RFgNjLcxq4W
0HZRbpixI04n5AFOU8N15/DznvfHxD8wwaz3/NZraj+11+2s1y0dB8cHb4Pddy+TGRjLezIZVbmZ
U+VYN4Ei+/tn+7Hbs0tgfREeTa3L0zqd1lk26c56FSO3PPzrreiyzNSOPN3y//SHrm0LFNDVf3wB
p2DxPcFil9de0xGhG6JnHzk/2pp7Dmzu8cuAo2c75zq2nBUzaxvG2CW8udBhVPbv+aZ7xw3HtNto
2r4e8IrL+3FXNSZ75At3HiMCtl/tQ8WZ6HlI9lmpm8qOA/0tmrPs+1oApe3wmu31z/Zjt8fuixWz
Ov55zG2D35ONDD5ynY5XHIyO6dmPnIIPnWrdglq6tRgNTG+AG+a4Vu5B1eraH14AvwwE9CxHx5YT
su8rnDQuOnPk+XL+6zhtjWeDssQYjmmvKcE+VvCj+ZaV1iX+r8+vmhuNUAbVKZvDblY7qI+a2X3X
/B2d3Q6P0ibox26P3Rche+7hKbcu4Akxn/y5dPWxtBbWBB9LtcEaTp1Zf4rmi9BObk6+akHcI3bO
t0NbfvanKEDxIqy15IBeI5yS/HJySn2tm1+xx9Y9GfTv7tEbRpnbSPWB1Mzyf6GtqZMdUzcKv7fz
UMHPKR8pjmCIPr+dqgqMKyYTaio7DgEfdt97U9rjPIzr2ykfzOx2CH2MyGaWH7s90ijri6yrEpli
OnVWJ5wqtYKYM38Wzf4SgSFLCr5TmjGkQ1xLfJf8OiQ9SvLrPbGuvHcnqRmiOXuCDk895Ev7fmVE
jgb0Jh+8M+2Xi7wk/oA/+ZtoaHnO59+UD7ktoQ1JcxvSVhjKifkBUv6ZC4fYMc2WE2I+SFNTwc+7
kvdw+ZdbXvX5PaEL2XHeL73sOAwnfFQ4Bd73Yz9guk+0wPhnL4TKtWP4E9JnA/2z/djtGWpnfWmI
i9uOkTpVmCJ1w3dI+WEM2nnmz/PGwS9zbpjPvSpUCzeM9Xsvqosdh6sLzJ/9+fPC47kxX1P75k08
OdFqglQoyxczCW3x44DxvIzjGXFtAddbIZ9MVZ5LBOD7ogiMZwQC4xmBwHhGIBYCvB9c7sDnG8gn
U1XAFzpmMN9AYP6MQGA8IxAYzwgExjMC4xlRAm1RVQtV0fxVSDuzVLjUv0d/rSM5tGDB/1OoKDRH
VSVr7wQWSKh7X/fK/7LgyBK75Rpql5VWhQ8c9h3h36Nf6r9HX2XYtKiqSgi8H65lv+Ar38z3ehbK
fXNmN87nKzjfSEYZnU1zp6S7NC3JmCQd5DQ3yZRDaUPqIjYxTcRXVo4epi8kKn2MHkaKNzF6GC0k
hXmYkboY2aRCohRjKilFkPk3WGu/onrlzB6l3HG4bzwaHoEvTITmEKWcIVXNiii5lDOquBYDdyXn
zyOT2wD0f5j6GkDisCXSP0g/Pdr9pRZWDlvPHebfkiaGaR0jxMmYRxK8zJa3J8oe+I7SeDMlkzFl
utpbGx03rNHIFMBLE8YYD9oN8jm6SP72n5ghnancrlkhvjDL2ukrZwQ0lHLHpaJxfPF2EXzwm9AN
bOcPwiblw5kKmRpx8r6FgbuC43lIVbYyApsDJMFaDwN06Xla7dg0yMqhoDbyBd+7EqDx9EAW4Bab
y8aWd/HfB84fIQL9MEDJYDKqsnFI1YiZrwugbOfK/YzwRu/g9DlkTwGbzMZa5y+n6PetWnR88fYC
a9rYzWzn22PMhGDpOpH4F4znlXo/2DoErQ+wza0P0GPye199EVqHwSknu8/WFeletLW19Qzbu5Xs
DRf98kNc1m+mdpqb4GZuISq9TKV2D9SRAu1poe7DTEV7Oq98mN3T1T0OvnKvba5p5ouX0caTVp5l
zq1EXT1ROn5QejJfx9qL94Mr/H6w1+V1KanoczhabAoXCFDUlKeHeXsOehib5ub6GtEmWl1dk3jL
ezDnlZdidtuanKZFZ8YoN/FNudHQl/Hx3krPnxnENquLfIDfhbYScs7tcJKXSGlQQyzwZQve4rQg
tnxvSlvDI+6JtlGSaOinShlzvmU59DAip7mZ4XQ17RpM/7J/u90GxV9+3PJFMpRrmw43ci+FMZ1+
0hRdrfke2YgYuCs+njMbI18ggdEpmulgxTfFu3lJ+rfEXBjggVWQjol7OG2TLT+x7TOUP6l+FWzS
15BIL9whmcEXjz8WE3Nvsr3TxjY6quMfX3WAZtOrIHxfiz3M9df5y+tdOnhiF8q1bbwzd4LtTDR8
hpoIf1rITgB8A9/yrQTkK7iSjDhay9QS0HVZDSO+u8gM5s8zyL/hy0PMK+js4FemLt1IRPQn0BjP
GM9VlUfhECCfTDWeSwTg+3UIjGcEAuMZgcB4RiAWArwfXO7A5xvIJ1NVwOfPyCeDwPwZgcB4RiAw
nhEIjGcExjMOQUVoV0Dj0vQQGM8+WGFBmvFiKVlSvXp20UXwoQoa+l8uSi9Zvl0RFeMW47kMosL7
o7HK76fNzfJSDhvLa2ixTYvSs1FaldFxPsd4Ljc/D6rqhAyQDovhtD1jd1FKF+tB6S2b5aXLAkt2
yulkGZMd+eRbEqV7cSlqOm1emGS3LKaYrTifWk9KNy1Kj3i2yWyalC6JfPB0UXwwBUKuDQMX43k2
pDVqMyXe2jNuSntYSWL8gJQAiP2wYY/N8tLYDM2SU05RM+LKvzpKg6z+sCXSr1lrX7R5YeD1kYlt
xFb9XptW4O4fLU4P6kde5143aAfCOXJBCZsf2wHQbGLgYjzPRgb0SZlMgPsF0Pazkl1kbxdAYXDs
iC3zvzJQ+HunnGJAdeX3qJRU5v71MECXZXvUMI8wQphdQ2q3Pc2uW5wenFA7OIHCEU5JIzyW2pkH
eK+AgVsBK329lbY2n2c3XL0mXRlL944b9hpZetyjtRhy3innhT55uvqQbiSuwzScPVJmG6JLFBej
5wn27SgWNveAFTdrujsoT5LvQ4nvb/jWD67o+VnUQB2fAWj36GM4pcxx74ZLFWK6n2qGwpG3GKkM
pYH5YtnPivscTlukXjNo97CdW2t+fIFshKlzPyL5hoZPWTHfKIOvtmpajKSwjRbEO1lJ3mKUMvVt
TeS4t48WCesTbrkNR/5haCOxnm+Htmd4Ra//wYPUCmt6+edGWZweZEFpZDtFQaaJtKyrZ6YBDuNb
kRjPZfDIzKoW6wzJZ2NC/h9ZSSEm3jwAMK5fOETCkLEiDqT63XIbjvxzjFSmYIimndCK1/mspwtS
nX1bd93i9GBCbnqE7YSnOmhZQ1y8/xjAPciPhPnz0uPiTDTdO7MsgWhJ3bQYvQpAPpnK+TPG8+Ih
GXOPsvzFH05wOiTVnFqUXgUB1b8mBeMZ47magOutkE+mKs8lAvD9OgTGMwKB8YxAYDwjEAsB3g8u
d+DzDeSTwUtsVWEaBwOBH24EAuMZgcB4RiAwnhEYz4hrAkhBgPFcDUjJkpKCyuQ1FThlEBjP1yKa
f3DUCP+gmZHXzIUeHCqM52WA3CsdMLZJ54QyByVRJZlHSAprlGeG/236ZiXUxzll7pc4p4zQmcKB
w3i+JlHoJ792Wpy85mujkSzADRPG6/QL3FdGmYRxNrSB7Ux93hgn1dEfW4d24MBVAK5PubrgawkF
i/FvvKLSjZwH+kOPqMBPBIelg4uHsnndT8iYwSlpGvk3rhUwpg+HT4OH6eZkMjntHoEAwFk6rNhf
Ut6D34Rjq5px4DDfuCbxxGHyqz2w+vW4y27D82fQXmA7jTONkzTMc6PPTOLAVQC+X3d18b8nm883
XZgSoFdzkghhStDjeVdChxt1toS7OLaTcsooiqpHceBwfr4mcb7hgpTtJvOzuMop6omJ8QuehNKp
81ecn2looXH9xs1iNIIDh/eDVQq8BcL7QQTmz4hrdXbCIcB4rh5gvoj3gwiMZwQC4xmBwHhGIPB+
cGUC+WSQT6aqgHzmM5hvIDB/RiAwnhEIjGcEAuMZgfGMQGA8rwQkKeYW0aXvwtxkL8ny1cl5H5VC
C92pWHhyKgCfP8+Bi5O4RMO7F2dm8fwwN4ivxxp1PDk4Py92mo7JYEXEMJkU+0JSSLNnSVHRILn1
o+zIUmhtkyx2qQCqJCo6p4Xpc6fomEypYjx9WhaX5HiKUcjAqELLUyFB5l91jSqi3E1EooqYouZF
YtAKszZY52GwiGcF43nRqBmBhzOm+DCJr58ZaR5wcclUbuAsMPTo7OsJgKmj5qYsQDZkKp8m8+jP
jLENro3pEUoV4+mzz8Roxvwko5CBJ8+GbgC4PW2FcqzqPs1U7qI7Z48lqbMs0UqMmxJpgyHA7+BZ
w3heXAJNNwMq7Bcgs5/MjTeBIrMqeQD6vSx2WO3YBZDvgHu3kBRO0/uP+GUpTqvaltKyjKrcPMTK
YY86RqzpCrAjgCMKZOjekNrRAWAOCnkWyNp+djX41FE8N5g/Lzp/JgkBja1ed0OwRQVVdAWJxPdJ
nDUXOgyAMx+SVzWf98naEgBlyjzSmBmSjuwoFuype809Bzy1rWpAuXFTB54bnJ8vBb2c48Wjejmu
gea9CGQx+ubozJHngRG+RD4F8HaQFoZrlSnj+TLjSLq1RrSJClbX/tBHWcBIlJw2kNxlJ54QjOdL
gmxBPEym0T5Qeb4gKH5Wo0Y4JQEUxtY9SQ46dZXO1vVEVikx4+mXoB1uJHd8xV/229fLaaHfd+UU
1loya0N3iB4aKp4QjOdLQjrWlSexNPwJ6bN83hxOSPlht3rywTvTABMNLc+RgxOqMDVOZe/MlfK+
ePolCCm5DED32hb7bjE89ZAvaH9lRI7SNgj/OWw/G0FUunfH9cHLHBl8/3kG+WQQ+HwDcW3OTjgE
GM/VA8wX8X4QgfGMQGA8IxAYzwgE3g+uTCCfDPLJVBXw+xTkk0Fg/oxAYDwjEBjPCATGMwLjGYcA
gfG84jEfrhnxj+cycLHCZAU5KySEkE+mEvD58yJxcUKYxok/WwKjs4oSNblQLIsnAOfnyzFNR2Xo
C4uhPnAoZ+gMGhbIXrKDEWg0yZKkMkqYg5QwRpRjAJoixblcxKJcM5J0UJeFFJuMLVmyV1r1MZIa
UpRSGM1MShTlJoD8EAyZOPIYz5cFdSOwYdxMbydXuox5JMFn0MOWmHC4ZqaOGuO/DxB/Lbob4Paf
mJQ66SVllDIcJYat81RjerT7Sy0jk9uY8neU05xSBjacfZ1fPW/XGM3Mtoh5dArAVMHAqyrG89In
0HTTr4IsgGIA3dxisKr8ehjIO3L5DlD6SRSuP0+K9A5GE/P1fjVNqowEU4S02rFpUFW2MvlXB1ps
3YzawdeC2zQzgnFwHatq/vwbOP4VgOthFxnOPe6GxnXKYpte0ymUDFvEav7Thzb12Ad9O4pFciCa
TMjWYDb4T9IRtK2IrFZrHVc294AVs2pOt5CakOR/BwnXw+J62CUFJYmxfHQvjGvGrY1Or58EhxLm
lhqRHtRygbLsMsddVcthrFldk3iLbITsuR+10uPCAA465huXDXmLEcfIFrwV4gXvQpvk1H4+vY7m
yMLJZpI8zHCaGL0N1pCNlIZ4qNRafdtop/1JAIVbmf5lP8nP4cGUumWaHpvIJ4PxfPmQiUq5SUb3
sofRvUChUzTTTu2mhhY6xsqTkyRJCH98FaWlO2FKtCz9W2I+XGrtp/qan/O9CbmZWwnft4qK/80O
KTrBMhEcc8yfq/fjhPkz5s+IKgU+yVz+sxMOAcZz9QDzRbwfRGA8IxAYzwgExjMCgfeDKxPIJ4N8
MlUF/D4F+WQQmD8jEBjPCATGMwKB8YzAeMYhuArQwLeCRcPxWDrg+89LDva6/dz0HKEcyHzVa7KH
7iXLiPtWKAY/C6unaye9P7WM7z8H3n/GeF76eO6Zj4gnVUG+kpmIkIkZOsZz+XjGfOOyhXVMBi0s
hUg6kQ6LYb50qinUJcXJDJ5M0l/dMiTtf2BxGVImprgBS6G6pKr5QUZJo0uCQqqsARicxuGtgDpQ
cBCWFq1DfPP+r/ftzc0cuNOA6W5oyL5NC289+U40Vxxq7SH/oXXNs/tah9jeEPzJO9nwtwxozf7d
N14qMv3xM0//zxpaNf3ehehUEcKh3IWXC1DcB8+bBc9dHudnL4bzOD9fhpnZpZpRBLjXBNgvgLaf
VR3h1DA2dvoWau8n0y4ll3nEIZaBtDrGz1N+DDRSVl/QdZZ0W5MRHOQKwPc3lh524kuCdTPZkBSB
RnAvK+vbUfRNrX7egS0qqGKgjNzzFXni0VSgzEs/uy26yqI3go3KGA5yBeD8fDlhU820u8Qxt9b8
+EJ50Xat9MHdKGj87ERnxl4lm5ty58JsYi7248hiPF8N5C04SHKGRgvinCSmKMiUXaZXg+Muh3Mv
22tsh7VfDUY43Mj5ZArdOlXqVNUR9iYZ8slgPF8dnIhKuycB9sSE/D+ygshURx3ZiKug3s2BBba3
xxCsPQHlfkU/zXYmbm05RDbP62KUiSKfTGXg8+flDnz+jM+fEfh8A3Gtzk44BBjP1QPMF/F+EIHx
jEBgPCMQGM8IBN4PrkwgnwzyyeCUVFUoYL6BwPwZgcB4RiAwnhEIjGcExjPiygGpYy438P3ni2Ae
7DDqlFH2HeTZDBo2icw8JCvzyVgxqz583jvO4PO6Ar7/PH/0EMwtkY3M95X6zZV8zOG+tKBeMF/N
4mnBfOPSpumYDFZEDFskaQhJYZ449IXEUB8kt3yUzZthMUJqmxWRkr9QefY36vsY54AuSnKKEcf0
hakOJA+KISKdVCV2xBQokYwVlp6x11NZMvVGDlKdohRjNiifjDQI6wt4QioA+WQuAocd5tzwvrgG
EdmAp8Znen6HzcgHGqcanjcpIQxBPMNqZ8IXpuqKTL51KHLkhVdqKatGqGEq9hzlkYEDDVQHWp87
e9trBrSeOv8dejQErSNnOrcVIV5/Zuta5rJV+80df2vQqr85WduoF6mNn24vUj6Zvyr4+WRwSppG
PpkFzMycHWZABUOADAnOggAdfADlfuh3l2mTWo3U6mOgbOHyAK/dDdY5WimZqfeMgE5GXU8LCqpj
YUjt2EqsDKonnExD7eDptq5AZguzsY7ZsKbwvhLvBxcbzt5tGY3rXtPZ2IVdB2wRuzi9tjC9idMt
kh9p9KG9KruJ+9z3G8YcHkbBYps7X2cb0XTKqYLhuPSqtNbiPf/aQ2yYtQ2USSZ8eDvg/SDeD14q
ejktzHGXHaZGA+37Tq1d/GEY87Fx5eMyI8sQsntDU64OHfQ+0H5KAx204M1kn/tQr9mpur7m/F8w
G+9zG+Z6PBd4P3jpIHd38RCbXQ/yfOPnp6DdZWKWRiEeJnPFmG54Kgn5Ba6qq68WGXUM0WmjOtvh
JGWLaYL2wDM86XaIc2owmIJTnE9mRtDrPRvkM4B8MhjPS4B0TNhIIrYnKu5+kxUM3y7lh93a3xbz
JMwnGlp8Y9q/hT8pblBFlmhEqI5BdeqEu0/T8ReNEwEfluhE65vKnZxkNzy1SvVsIJ8M5s9XDU25
3EXT8lLEzQU9Xsb8GfPnK4b/KFfKxQMbDzPbRGMcxw3n5xULXG/lW2+FF6vqOZcIvB9EYDwjEBjP
CATGMwKxIOD94HIHPt9APhm8xFYVpnEwEPjhRiAwnhEIjGcEAuMZgfGMmAe0JRe8JBVEJazA9+vm
wRCjR+XJQIGiz9M4EUxehK6jtF7OL4hPRvtQsXZS8I7xlV+Y9t6vW4F8Ba09Q0NDc4uEJ6aDBbcM
zdM4EbyYaOvQvFRssVlVeyPZSL2frwD/PuwM8hWQiS+qMGqYPkriIoQ5awAnhUluvYtLyKCFpZDG
iGCYvMLoX1RRoMwuSVVSSLJg08xYsqRyQZD7yJFTDq68FhZDPLmw/TYrom6rEGnWBuJTSPEGjipU
mlQ1yWKXSqxIIr1MKIMwWMTEogJW4vxsM8T8yYF9T/306cmDJOX61RMNMlvFGheyIcWwGWJaP/j1
vr25mQN3sgImLzMymGIod+HlAiWD+e6jRFuDyFffhkZZzhaY4FDoh/mmOsMuJ7Dl9+aAEtEQ/7bf
WnE8aqtAvC4XMWoorcx/2sbCtfWRM09/k1HNTB997sG/LcJ0KNu4ox8K++CvLJyfcX72ZmbOELNT
BesmUGSAXS2g7WJVxgAMesuz+1VQBLiXkxMweU4G882CrtNV2ZraLzMimcx+gMLAmLNS+/0CWP/m
lIMrr7hENLZfc1BwF3fvGoSB+8n2NKOVoUirY3x6z3fAvVsA6om7I0z700dxIsb7wTI3Wj6GmOOG
U8hJXHwSKctH+EKr+24rQM9WV9g24ugke7QWg97kgcM748h7tmapsH3JcL34m2I1FzqMHnojOBOl
y8WV79wLeD9Y/n5wZQ/GcY8hhs/KvVrJ4zNaZXlHGuN4uSl3LryNPWmj1DAOzYynqOajulsOrrxn
6/gsFWY62LhRTjwDEJ058jy1mhuNfIqlLztxHq6ElR3PQh+oJAOQmhlRDH121g5rA0uy85w8xo48
gRPIKKo6MkMO10C7yGlmwiQdaG+W2QeCpuEfS7jl4MrnXSIa26+wltw22rbz7dAWZIduhxv5U8LC
2LonyaZTVYGxMZnIJ4PxXBbDn5A+GwEYyon5AZ6zGl1W2i+RiYq7JwGeaOHydzACmUFdjFFSr0OS
cZrSzHTlyadh/LMXyG/xISo32NvvloMrn4lKuyf9fn9lRI46tguGaAYn6HElx99tnmhoeY5sTuhC
llEZIJ8M5s+XMRG/ysD8GfPnJcq+cQiuOeD6lMXDuEZmJzwTGM/VA8wX8X4QgfGMQGA8IxAYzwgE
xjMCgfGMwHhGIDCeEQiMZ8TcyFxl/WvLAMYzAudnBALjGYG43MD3n1d6/lwNwL/XVo0nc5Gfh0ud
0K4BA5hvIDB/RiAwnhEIvB9EIBaTSeP9YBWcRH5PmKG/53tv5eqw7YJUvXuw+OJ8e/dw8Xm3gFd5
ra7kFON5+YczP6vs/7zD2YmEuH00f1UH8cX69tQzMN8WZEp6WtEp5s8rEnH/rLfYD9ESfRCX1BvO
z9U2VS8mVVmEaqb0wffCfcfn3YL4vDuM8Vw1U26G/s/M+/7eSTfIdqGq4Gou0vcsO4tqQTkdjOeq
yiHs7HKBacciVOOX7PtSW1BeB/PnFZpuZC4xW7j0VCd+6Rn5bB2M55Uc+ot/l2mp3oJa6rep8PuU
KohN/8Oz+Z1P39PfhaoGnV6CgfhCGl/u+XMZnQzGM6KaPtqYbyCqCRjPCIxnBALjGYHAeEYgMJ4R
KxO+77txoTBiuSJeJp7xSTRimSKD+QYC82cEAuMZgcB4RiAwnhErHPVz3y7aqLonH9jDlRTPpbP2
dNX3u1B9PawJHs5gvoFAYDwjEMshnjPzrJ0ll8l4pdf0d+qZsk3MVFGv3R5WaviyP41LxVdwMeax
6rwpWba9jlfraVx4vpHJ2J9v9/OaYf/sGv88wCUzJZ9vW8yTvgYnaqeJ/j47m0wV9Jq3CAK9rIrT
uOD5uRzpWCYerPEfO4x5LvFHkFTvGg3ouPd/dpO9Hi3nXtPWBJpYFadxkflGPGP/K7n8xGddmmZd
ouLL4LIVL9vCeHC7HHudKTmLs7uxzE/jEvJ9xX2cwhcf03hmGWXTc9wGLa9ez4NFZnmfxvqlHSz6
mb4IC1nGR2K9XAI6Hmh5lfd6WXdosc+f44wUMj7fB1vB2sy1+ciHXX4r9SlToY/LudeZeRcum9NY
v8DexytfYLwaHuhByXjGreQ112C+UdImf5Ppnt3yKul12d4s+9Po4/vyZqZS1qTp6ntbp/T9jerr
Yen7G/EKSUNVdDZe4bwiVgwyUI3v3GE8r1RU5/uj5eN5uurPZqHqezizIj+l9Svno4s9XAHA90UR
GM8IBMYzAoHxjEBgPCMwnhGI5Q7/8zokzEVUUTwjXS4C8w0EAuMZgcB4RiAwnhEYzwgExjMCgfGM
QCAQiDL4/9Nc4yv8U6HQAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Selection, enrolling, randomization.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2016-06-30 11:19:16 +0100" MODIFIED_BY="Tracey Remmington" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Selection, enrolment and randomization</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtAAAAPACAYAAAAc9k6zAABZaklEQVR42uzdC4wt933Y9wV2eXfv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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>